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 Abstract 
        Diabetes mellitus is becoming a major health problem in Sudan, due to improvement in 
the standard of living, change in life style which was accompanied by high caloric intake and 
less physical activity.  
Four hundred type 2 diabetes mellitus Sudanese patients were studied together with 106 
healthy controls. The patients' age at the onset ranged from 40 -80 years, with a mean duration 
of diabetes of 10 years. Female to male ratio was 1.3: 1.  48% of patients were overweight and 
24.8 % were obese, a positive family history of first degree relatives was obtained in 56.5 % 
and about 70.3 % of the patients were on regular follow up in various specialized and non-
specialized diabetic centers.  
A rise in prevalence of vascular complications among Sudanese diabetics was found compared 
with previous studies. About 69.5 % of the patients had one or more diabetic vascular 
complication.  Their distribution was as follow: Diabetic retinopathy was found in 47%, 
diabetic nephropathy 33 %, diabetic neuropathy in 16.7 % and coronary heart disease in 12 %. 
Microangiopathic complications of diabetes were significantly related to the duration of 
diabetes and the degree of hyperglycemia (p <0.001) using Chi square test. Macroangiopathic 
complications were significantly related to ageing and hyperglycemia. Patients with good 
metabolic control (Fasting blood glucose < 10 mmol /L) had less prevalence of diabetic 
complications than uncontrolled patients. 
 
In the present study we studied the association of haptoglobin phenotype with development of 
diabetes & its vascular complications. Hp phenotype 1-1 was higher in diabetics compared to 
controls, and it was also more common in complicated than uncomplicated groups, but the 
difference was not significant. (P >0.05). The Hp2 allele occurred at a percentage of 83 % in 
nondiabetics and 79.5 % in diabetics, but no statistically significant variation was detected in 
Hp distribution between the two groups.  
The results obtained showed there was no association between Hp genotype and type 2 
diabetes mellitus and diabetic vascular complications.  
We studied the association of haptoglobin phenotype among 96 patients with chronic renal 
failure (CRF).  The main causes of chronic renal failure in our group were diabetes mellitus 
26%, chronic glomerulonephritis 20.8 %, hypertension 3.4 %, obstructive renal disease 2.9 %, 
and most the cases were of unknown etiology 36 %. No significant association was found 
between the distribution of different haptoglobin phenotypes and chronic renal failure, and / or 
different causes.  
The results presented in this thesis showed no association between haptoglobin phenotype and 
both diabetes mellitus and chronic renal failure. 
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 Chapter One 
Introduction and Literature Review 
 
Diabetes mellitus is a worldwide health problem. Many countries at an early stage of 
modernization are undergoing a demographic transition with both the affluent and 
poor urban dwellers rapidly adopt the Western lifestyles with an increase in the 
consumption of fat, sugar and salt. In Africa, these lifestyle changes have evolved 
along with an increasing prevalence of diabetes mellitus, obesity and hypertension 
in both rural and urban communities [1]. 
 Sudan is one of the largest countries in Africa, with an area of 2.5 million square 
kilometers. It is a multi-ethnic, multi-cultural country, and geographically is a 
diverse mixture of ecologies. Most of the populations have a genetic admixture of 
Semitic and Hamitic strains. Diabetes mellitus in Sudan, as in many developing 
countries constitutes a growing health problem with a major impact. 
 
1.1. Historical Background: 
A polyuric state has been known from ancient times and was reported around 1500 
BC in the Papyrus Eber's found at Luxour in Egypt. The excessive indulgence of the 
patients in eating and drinking led it to be described, about 6 AD, as "the disease of 
rich" [2]. The name "diabetes" is attributed to Demetrious of Apamia (2nd century 
BC) and is derived from the Greek word diabeinein, which means "pass through".  
Aretaeus (81-138 AD) gave the first description of the symptoms of diabetes: 
intolerable thirst, passage of large amount of urine, and the two stages chronic and 
acutely fatal. 
The fact that diabetic urine tasted sweet was subsequently emphasized by Arab 
medical tests during the 9th to11th century, when Arabic medicine was at its peak.  In 
1674 Thomas Willis recognized the fundamental component of sweaty urine and 
added the decorative epithet "Mellitus" to the name of the disease. The research of 
Paul Langerhans (1847-1888) and many other workers in the 19th century led to an 
insight into the significance of the islet-cells of the pancreas in diabetes mellitus. In 
his thesis of 1869, Langerhans described the anatomy and histology of the 
pancreatic islet-cells, although he was not able to express an opinion on their 
function. In 1892, Laguese surmised the endocrine secretion of the islet-cells and in 
1898; Naunyn advanced a comprehensive theory of diabetes mellitus. 
Further developments were concerned with the isolation and discovery of the active 
agent insulin, in 1921 by Frederick Banting and Charles Best. Major advances in the 
understanding of diabetes and metabolism have included, the sequencing of insulin 
in 1955, measurement of insulin concentration in 1959, isolation of proinsulin in 
1967, identification of specific insulin receptor in 1971, and  the sequence of insulin 
receptor gene in 1985  [3 ]. 
 
1.2 Definition of Diabetes Mellitus 
The World health organization Expert Committee on Diabetes [4], defined diabetes 
mellitus as a state of chronic hyperglycemia, which may result from several 
interacting genetic and environmental processes. The excessive elevation of blood 
glucose concentration results from deficiency or reduced action of insulin. 
Epidemiological studies confirm that the clustering of glucose intolerance, 
hypertension, abdominal obesity, and dyslipidemia, known as metabolic syndrome, 
occur together commonly in certain people. A wide variety of ethnic groups, 
including Europids, African-Americans, Asian Indians and Chinese, Australian 
Aborigines, Polynesians, and Micronesians, have been found to have such clustering. 
In 1988, Reaven [5], focused on this cluster, naming it "syndrome X", with insulin 
resistance possibly being the common etiological factor of the individual 
components of the syndrome. In 1998, the World Health Organization (WHO) 
proposed a unifying definition for the syndrome and chose to call it "metabolic 
syndrome" rather than "insulin-resistance syndrome" [6]. In 1999, [7] chose the term 
"metabolic syndrome X" to describe the clustering of cardiovascular risk factors in 
honor of the term used in Reaven’s articulate description. Using the 1998 WHO 
proposed definition of metabolic syndrome, studies of a Scandinavian population 
revealed that 10% of those with normal glucose tolerance, 50% of those with 
impaired glucose tolerance, and 80% of type 2 diabetic patients had metabolic 
syndrome. Moreover, it has also been found that the presence of metabolic syndrome 
is associated with a threefold increased risk of coronary heart disease, myocardial 
infarction, and stroke and a three- to fivefold increased risk of cardiovascular death.  
Metabolic syndrome is believed to be attributable to the collective effect of genetic 
predisposing factors in combination with specific environmental factors, such as diet 
and stress. There are several candidate genes involved in metabolic syndrome, 
including the genes for the ß2- and ß3-adrenergic receptor, lipoprotein lipase, 
hormone-sensitive lipase, peroxisome proliferators–activated receptor- , insulin 
receptor substrate-1, and glycogen synthase [8]. 
 
 
1.3 Classification of Diabetes Mellitus 
The concept of classification diabetic persons  into different categories needs more 
informations, which includes the patient's nutritional status, weight and height, 
clinical history, findings on examination, medication, in women presence or absence 
of pregnancy, and additional tests including urinary ketone levels and perhaps the 
blood C peptide concentration. Although an individual can be assigned to only one 
class, that designation may change with time [3]. The present classification of 
diabetes most widely used is that recommended by the National Diabetes Data 
Group and subsequently endorsed by the World Health Organization. This 
classification is primarily a clinical classification of diabetes because in most 
instances the etiology is unknown. The need for a standardized classification arose 
out of the recognition that diabetes was a syndrome rather than a single disease and 
the different terminologies which emerged. While certain types of diabetes can be 
classified according to specific etiology or associations with specific syndromes, the 
vast majority cannot. Insulin-dependent and noninsulin-dependent diabetes usually 
represent syndromes whose etiopathology is believed to differ and their clinical 
characteristics are usually distinctive [9]. The concept of insulin dependency 
requires clearer definition for operational purposes. Biochemical parameters (e.g. C-
peptide responses) may help. Attempts to combine clinical manifestations and 
pathogenic mechanisms in a single classification (e.g. IDDM/ NIDDM versus Type 
I/ Type II) should be handled with care. If the term Type 1 is to be retained, it 
should be applied to a defined pathogenic process, not to a clinical type of DM. The 
term Type II is inadequately defined at present [10]. As evidence of etiological 
heterogeneity has increased there has been a tendency to adopt the terms Type I and 
Type II diabetes to indicate different etiologies, although the original usage of these 
terms was as a clinical classification to differentiate between insulin dependent and 
non-insulin-dependent disease. At present the use of the four terms to describe the 
common types of diabetes leads to confusion, which could readily be resolved by 
arriving at agreed definitions for each of these terms. (Table 1) The classification of 
diabetes most widely used at the present time is that suggested by the National 
Diabetes Data Group (NDDG) in the United States in 1979, which was subsequently 
recommended by the World Health Organization (WHO) Expert Committee on 
Diabetes Mellitus in 1980. It should be stressed that this classification was intended 
to be a uniform framework for clinical and epidemiological research, and that the 
classification would almost certainly have to be modified on the basis of new 
knowledge in the future [11]. 
 
 
 
 
 
 
Table 1.1 Etiologic classifications of diabetes mellitus [12] 
 
I. Type 1 diabetes (ß-cell destruction, usually leading to absolute insulin deficiency) 
    A. Immune mediated 
    B. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin 
deficiency to a predominantly secretory defect with insulin resistance) 
III. Other specific types 
    A. Genetic defects of ß-cell function 
        1. Chromosome 12, HNF-1  (MODY3) 
        2. Chromosome 7, glucokinase (MODY2) 
        3. Chromosome 20, HNF-4  (MODY1) 
        4. Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4) 
        5. Chromosome 17, HNF-1ß (MODY5) 
        6. Chromosome 2, NeuroD1 (MODY6) 
        7. Mitochondrial DNA 
        8. Others 
    B. Genetic defects in insulin action 
        1. Type A insulin resistance 
        2. Leprechaunism 
        3. Rabson-Mendenhall syndrome 
        4. Lipoatrophic diabetes 
        5. Others 
    C. Diseases of the exocrine pancreas 
        1. Pancreatitis 
        2. Trauma/pancreatectomy 
        3. Neoplasia 
        4. Cystic fibrosis 
        5. Hemochromatosis 
        6. Fibrocalculous pancreatopathy 
        7. Others 
    D. Endocrinopathies 
        1. Acromegaly                             2. Cushing’s syndrome 
        3. Glucagonoma                          4. Pheochromocytoma 
        5. Hyperthyroidism                     6. Somatostatinoma 
        7. Aldosteronoma                         8. Others 
    E. Drug- or chemical-induced 
        1. Vacor                                    2. Pentamidine 
        3. Nicotinic acid                       4. Glucocorticoids 
        5. Thyroid hormone                  6. Diazoxide 
       7. ß-adrenergic agonists            8. Thiazides 
        9. -Interferon                         10. Others 
    F. Infections 
        1. Congenital rubella 
        2. Cytomegalovirus 
        3. Others 
    G. Uncommon forms of immune-mediated diabetes 
        1. "Stiff-man" syndrome 
        2. Anti–insulin receptor antibodies 
        3. Others 
    H. Other genetic syndromes sometimes associated with diabetes 
        1. Down’s syndrome                     2. Klinefelter’s syndrome 
        3. Turner’s syndrome                    4. Wolfram’s syndrome 
        5. Friedreich’s ataxia                     6. Huntington’s chorea 
        7. Laurence-Moon-Biedl syndrome   8. Myotonic dystrophy 
        9. Porphyria                                           10. Prader-Willi syndrome 
        11. Others 
     IV. Gestational diabetes mellitus (GDM)    
 
Patients with any form of diabetes may require insulin treatment at some stage of their disease. 
Such use of insulin does not, of itself, classify the patient.  
 
1.4 Prevalence of Diabetes mellitus 
The revision of the classification of diabetes mellitus, to differentiate clearly between insulin-
dependent (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM), and the provision of 
unambiguous guidelines for diagnosis constitute important recent developments in diabetes 
epidemiology. However, the knowledge even of the prevalence of NIDDM remains surprisingly 
incomplete for many areas of the world [13]. An Epidemic of non insulin –dependent diabetes 
mellitus (NIDDM) is occurring across the world, particularly affecting developing countries and 
migrants from there to more industrialized westernized societies. Diabetes has reached epidemic 
proportions in many populations. Current estimates suggest that the number of persons with 
diabetes will reach 250 million by 2010 and 300 million by 2025. The majority of these patients 
will have type 2 diabetes and reside in developing countries [14]. Because of the asymptomatic 
nature of type 2 diabetes, 33–50 % of individuals with the disease do not know they have it [15]. 
Since 1988, the World Health Organization has been collecting standardized information on the 
prevalence of diabetes mellitus and impaired glucose tolerance in adult communities worldwide. 
Within the age range 30 to 64 years, diabetes and impaired glucose tolerance were found to be 
absent or rare in some traditional communities in Melanesia, East Africa, and South America. In 
communities of European origin, the prevalence of diabetes and impaired glucose tolerance were 
in the range of 3% to 10% and 3% to 15%, respectively, but migrant Indian, Chinese, and 
Hispanic American groups were at higher risk (15% to 20%) [16]. The projections of the WHO 
suggest a 35% increase in the prevalence of diabetes. This increase is explained by a progressively 
more sedentary life style, the overabundant and attractive food sources, the increase in life 
expectancy leading to diabetogenic ageing and, more specifically for Europe, the baby-boom 
effect after the Second World War, and finally, the changes in diagnostic criteria (fasting glucose 
> or = 1.26 g/L (7 Mm) on two occasions, serum glucose > or = 2 g/L 2 hours after a loading dose 
of 75 g of glucose [17].   Since the wealth brought by oil dramatically changed living conditions in 
the Arabian communities. Recent surveys have confirmed the epidemic of diabetes mellitus in 
Oman [18], Saudi Arabia [19], and Egypt [20]. 
Diabetes is an important cause of morbidity and mortality in Africa. Recent data on type 2 
diabetes prevalence indicate low rates in some rural populations, moderate rates similar to those in 
developed areas in some countries, and alarmingly high rates in others [21]. The prevalence of 
diabetes in African communities is increasing with ageing of the population, dietary changes, 
reduction in physical activity, increasing obesity, and lifestyle changes associated with rapid 
urbanization and westernization. Traditional rural communities still have very low prevalence, at 
most 1-2 %, except in some specific high-risk groups, whereas 1-13 % or more adults in urban 
communities have diabetes. Type 2 diabetes is the predominant form (70-90 %), the rest being 
represented by typical type 1 patients and patients with atypical presentations that require more 
pathophysiological insight [22]. 
Diabetes prevalence in Algeria was 8.2 % [23], in Kampala and Mokono, was found to be about 
8.1 % [24]. The prevalence of type 2 DM was 8.0 % in Cape Town, South Africa [25]. 
The prevalence of diabetes in Nigeria increased from 2.8 % in the year 1997 [26] to 7.7 % in 2003 
[27]. In Tunis the prevalence is 7.2 % [28], in rural Sierra Leone, 2.4 % [29], and the least 
prevalence was in Libya 0.19 % [30]. 
The combination of the rising prevalence of diabetes and the high rate of long-term complications 
in Africans will lead to a drastic increase of the burden of diabetes on health systems of African 
countries. The design and implementation of appropriate strategy for early diagnosis and 
treatment, and population-based primary prevention of diabetes in these high-risk populations is 
therefore a public health priority [22]. Epidemiological analysis of diabetes shows its invalidating 
feature, especially in terms of fatal vascular risk, which may be attenuated by correction of all 
associated metabolic abnormalities. The progression of the incidence of diabetes should alert the 
physician to be more attentive in the diagnosis and management of diabetes, especially with 
regards to early dietary intervention [17].  
 
1.5 Diabetes mellitus in Sudan 
Sudan has had contact with Middle –East and Mediterranean civilizations since ancient times. The 
western part has many contacts with west Africa, and the eastern part have maintained close links 
with the countries of the Indian Ocean. The population in the north-eastern parts of the country 
undergone ethnic absorption of immigrant Arabs during times of Islamizing, and culturally 
became Arabised. About 70 % of the Sudanese population lives in the northern part of the country. 
Twenty one percent of the populations are urban settlers, and an estimated 10 % of the rural 
inhabitants are nomads. Regular internal migration in different parts of Sudan has taken place 
from rural areas and small towns to big cities, particularly to the capital, Khartoum. This has been 
compounded by displacement of a large proportion of populations from drought and famine prone 
areas in western and southern regions. In recent years permanent external migration has also 
occurred [31]. These cultural changes have lead to considerable progress in educational and health 
establishment as well as improvement in the standards of living. These social and economic 
advances were accompanied by a change to a modern life style, characterized by higher caloric 
intake and less physical activity, and the emergence of non communicable diseases such as 
diabetes mellitus a major health problem causing high morbidity and mortality. It can be estimated 
from the hospital records that the number of diabetic patients is increasing in all socioeconomic 
classes. Type 2 DM accounts for 75% of all diabetic patients attending the outpatient diabetic 
clinic in Khartoum [32]. The overall crude prevalence of diabetes mellitus and impaired glucose 
tolerance in the total population of the northern part of Sudan was 3.4 % and 2.9 % respectively. 
The highest overall prevalence was in the northern parts of Sudan 5.5 % and the lowest in the 
western desert populations 0.9 %. The prevalence of undiagnosed diabetes was 2.2 % of the total 
population. The high prevalence of undiagnosed diabetes will have a profound impact on the 
community in general and on the public health services in particular. In Danagla community of the 
northern state the prevalence was 8.3 %, while in a sub group of this community, with Egyptian 
descent the prevalence was 10.8%. There were no urban /rural or male/ female differences in 
prevalence [33].   
1.6 Type 2 Diabetes Mellitus: 
1.6.1. Pathogenesis of Type 2 Diabetes: 
Type 1 and type 2 diabetes are the two main forms of diabetes.  Type 1 diabetes is characterized 
by an absolute insulin insufficiency caused by the immunological destruction of pancreatic ß-cells, 
which produce and secrete insulin, and it accounts for 10% of all cases of diabetes. Type 2 
diabetes is more complex in etiology and is characterized by a relative insulin deficiency, reduced 
insulin action, and insulin resistance of glucose transport in skeletal muscle and adipose tissue. The 
manifestation of frank type 2 diabetes is a continuum of insulin resistance culminating in the 
failure of augmented insulin secretion to compensate for insulin resistance, and the progression to 
full diabetes ensues when pancreatic ß-cell hypersecretion of insulin fails to compensate for insulin 
resistance [34].  Commonly found alterations of insulin secretion in type 2 diabetic patients include 
reduced or absent first-phase response to intravenous glucose,  delayed or blunted release after 
ingestion of mixed meals , alterations in rapid pulses, and ultradian oscillations. In addition, 
second-phase insulin secretion and response to nonglucose stimuli may also be reduced [35]. It 
was found  that type 2 diabetic islets release less insulin  in response to glucose  and  this was  
accompanied by altered expression of glucotransporters (in particular GLUT2) and of glucokinase. 
GLUT2 has high transport capacity and Km for glucose, so that the rate of transport of glucose by 
GLUT2 is largely dependent on the ambient glucose concentration.  On the other hand, 
glucokinase exhibits low affinity for glucose, and it is considered the rate-limiting step for glucose 
metabolism in the ß-cell. Alterations of both proteins (and in particular of glucokinase activity) 
have been associated with diabetes. In type 2 diabetic islets there is 40–50% decrease of GLUT2 
and glucokinase mRNA expression correlated well with the observed 50% reduction of glucose 
oxidation [36]. The defect of insulin release upon non-glucose stimuli was less markedly affected, 
as amino acid-induced insulin secretion is better maintained in type 2 diabetic islets. It was found 
that arginine and glibenclamide induced an early insulin secretion phase from the diabetic islets. 
Both arginine (by increasing intracellular positive charge) and sulfonylurea (by inhibiting K+ loss 
from ß-cell) cause depolarization of ß-cell membrane This event is followed by Ca2+ entry, 
increased cytosolic Ca2+ concentration, and translocation and exocytoses of insulin granules. In 
summary it is believed that the defects of glucose-stimulated insulin release in type 2 diabetic ß-
cells lie between glucose transport and depolarization of the cellular membrane. In this regard, 
alteration of mitochondrial function might play a crucial role, as recently suggested by [37]. In 
type 2 diabetic islets reduced activation of AMP-activated protein kinase (AMPK) was observed. 
AMPK is a multisubstrate kinase regulated by AMP, and it controls a number of metabolic 
enzymes with the aim of reducing cellular ATP consumption during conditions of metabolic stress. 
Activation of AMPK is considered to have beneficial effects on diabetes because it improves 
insulin action in the muscle and liver. This kinase has been recently implicated in the control of 
insulin secretion [36].  Many studies suggest that type 2 diabetic patients are subjected to chronic 
oxidative stress. Hyperglycemia and increased free fatty acid concentration can contribute to the 
formation of reactive oxygen species, which in turn damage cell proteins and DNA. In islet ß-cells, 
oxidative stress is even more dangerous than in other tissues because of the low intrinsic 
antioxidant capacity of the ß-cell [38].  
 
1.6.2. Histology of the pancreas in type 2 diabetes: 
The observed pathologic changes in the pancreas of type 2 diabetic patients are very variable. A 
slight reduction in the number of β-cells may be demonstrated. The same reduction already can be 
seen in many elderly healthy persons. In 1901, deposits of a hyaline substance have been 
demonstrated within the islets of Langerhans of diabetic patients. This material was later identified 
as amyloid. Recent studies however revealed that the peptide structure differs from systemic 
amyloid peptide. Thus the term Islet Amyloid Polypeptide (IAPP) was introduced.  It is a 37 
amino acid peptide, which shows a 46 % homology with calcitonin – gene related peptide, a 
hormone formed in the C- cells of the thyroid by alternate DNA processing of the calcitonin gene. 
Considerable variation in the occurrence of islet amyloid in type 2 diabetic patients has been 
reported, with a prevalence varying from 25 to 92 %. In a recent study in Pima Indians, deposition 
of IAPP could be demonstrated in pancreatic islets of 77% of diabetic persons, while it was found 
in less than 10% of non- diabetic individuals. No relation was found between the occurrence of 
amyloid deposits and body mass index, fasting blood glucose level or age   [39]. 
Histologically, the amyloid is seen between the islets capillaries and the endocrine cells. The 
fibrils lie in invaginations of the plasma membranes. IAPP probably originates from the insulin- 
producing beta cells. Its presence was also demonstrated inside the beta cells of diabetic and non- 
diabetic subjects. Its physiological role is not clear yet. Both involvement in the intracellular 
processing of insulin, regulation of enzymatic activity and paracrine modulation of insulin 
secretion have been suggested as main action of the peptide.  Its co-secretion with insulin and 
possible vasodilating effects may increase the blood flow during insulin secretion. However direct 
inhibition of insulin secretion might be a direct effect. In addition, it was shown that IAPP can 
modulate insulin action and produce insulin resistance [40]. It is not confirmed yet whether the 
formation of islet amyloid precedes the onset of glucose intolerance and diabetes, or whether it is 
formed secondarily after the onset of the disease, either directly released or linked to increased 
insulin biosynthesis. However the accumulation of amyloid over many years can lead to slowly 
progressive disruption of the islet architecture and possibly to the abnormalities in the secretion of 
insulin, as found in type 2 diabetic patients [41]. 
 
1.6.3. The biosynthesis and secretion of insulin 
The B cell in the pancreas is a classical example of those cells which has both an 
exocrine and endocrine function. It synthesize, store and secrete polypeptide products. 
Its main product is insulin. The islet B cell is responsible for (a) the synthesis of proinsulin 
(b) proteolytic cleavage to produce insulin (c) Storage of large quantities of insulin in 
membrane limited vesicles and (d) the secretion of insulin in response to specific stimuli 
[3]. 
 The preproinsulin the ultimate precursor of insulin is located on the short arm of chromosome 11, 
close to that for insulin –like growth factor2 (IGF-2). Transcription yields preproinsulin, which is 
cleaved by protease enzyme in the endoplasmic reticulum ER to yield proinsulin. A characteristic 
feature of beta-cells is the highly developed ER apparently due to a heavy engagement in insulin 
secretion. Endoplasmic reticulum (ER) can sense and transduce apoptotic signals. Beta-cells are 
most susceptible to ER stress. ER stress-mediated apoptosis in beta-cells plays an important role in 
the development of diabetes [42].  
  In the rough ER the proteolytic enzymes remove the signal peptide from preproinsulin and 
convert it into proinsulin. The Proteolytic removal of the NH2-terminal transport peptide is 
necessary to allow correct conformational development, including the formation of native disulfide 
bonds, which not only stabilizes the molecule but allows expression of authentic biological and 
probiological activity [43]. Proinsulin is packaged in vesicles and transported to the golgi 
apparatus, where it is packaged in vesicles that are enclosed by a membrane containing an ATP- 
dependent proton pump.  Proinsulin is converted to insulin by the proteolytic removal of the 
connecting C peptide. The main function of the C-peptide is to bring the B and A chains together 
so that initial folding and disulfide bond formation in the endoplasmic reticulum can occur 
intramolecularly. The C-peptide spacer sequence also provides suitable flexibility for presenting 
the dibasic cleavage sites for endoproteolysis by prohormone convertases [44].  
Insulin is a peptide hormone, consists of a 30-residue ß -chain and 21-residue α-chain. Insulin has 
a lower solubility and so co precipitate with zinc ions to form microcrystal within the secretary 
granules. Insulin and C peptide are stored together in the granule sac and are ultimately released in 
equimolar amounts under normal conditions, 95% of the hormone is secreted as insulin and less 
than 5 % as unconverted proinsulin [3]. 
 
1.6.4. Normal and altered insulin secretion: 
Insulin concentrations are normally determined by a feed back control system that is responsive to 
the prevailing level of plasma glucose. Sensitivity of the pancreatic β- cell to glucose is 
determined by the sensitivity of peripheral tissues to the action of insulin,  with insulin resistant 
subjects having higher insulin levels and insulin secretion rates than insulin sensitive subjects. 
Glucose stimulates both insulin secretion and proinsulin biosynthesis through signals associated 
with its metabolism in the β- cell of the pancreatic islet. Glucose metabolism increases the ratio of 
ATP/ADP in the β-cell causing the closure of tonically active potassium (K- ATP+) channel. 
Subsequent membrane depolarization opens L-type voltage-dependent calcium channels. The 
resulting calcium influx leads to secretion of stored insulin [45].  ATP sensitive potassium (K- 
ATP+) channels reside in the plasma membrane of many excitable cells such as pancreatic beta-
cells, heart, skeletal muscle and brain, where they link cellular metabolic energy to membrane 
electrical activity. They are composed of two subunits, K+ ion selective pore (Kir) and 
sulfonylurea receptor (SUR). In addition to the central role of pancreatic beta-cell, K -ATP 
channels in glucose-mediated insulin secretion, several lines of evidence support the hypothesis 
that K- ATP+ channels modulate glucose transport in the insulin target tissues. Inhibition of K-
ATP+ channels by glibenclamide or gliclazide or an increase in intracellular ATP during 
hyperglycemia (glucose effect) or exercise facilitates glucose utilization, while activation of the 
channels by potassium channel openers, hypothermia (cardiac surgery), or ischemic damage 
(myocardial and brain infarction) reduces glucose uptake induced by insulin by  or hyperglycemia 
[46].       
Insulin is also secreted in response to amino acids and fatty acids. It was found that long chain 
acyl-CoA esters, metabolically active forms of fatty acids, are the most potent and physiologically 
important activator of K-ATP+ channels. The magnitude of this response is modulated by a variety 
of neural (sympathetic, parasympathetic and autonomic) and hormonal factors (glucagons, 
glucagons-like peptide 1, gastric inhibitory polypeptide and somatostatin) [47].  
Normal insulin secretion shows a rapid response to glucose and a complex pulsatile profile. The 
biphasic kinetics of insulin release is probably explained by the presence of a small population of 
docked granules, released during the first phase of insulin secretion, and the subsequent arrival of 
"newcomer" granules targeted to the plasma membrane and released during the second phase of 
insulin secretion [48]. 
Early manifestations of disordered B-cell function include delayed and blunted responses to 
glucose, temporal irregularities in the pulses, oscillations of insulin secretion, and loss of the tight 
coupling between pulses of insulin secretion and pulses of glucose. Diabetes is also associated with 
impaired conversion of proinsulin to insulin. As a result, circulating proinsulin concentrations 
comprise a greater proportion of total immunoreactive insulin concentrations in diabetic than in 
normal individuals [47]. 
 
1.6.5 Insulin Receptor 
Insulin regulates numerous diverse metabolic processes through its binding to a high affinity cell 
surface glycoprotein receptor. The receptor is widely distributed among tissues and plays an 
essential role in determining the tissue response to insulin stimulation. Humans and mice lacking 
insulin receptors are born at term, but do not survive long, suggesting that insulin receptors are 
essential for postnatal growth and fuel metabolism, but are not required for fetal metabolism [49]. 
The complete insulin receptor is a heterotetrameric membrane glycoprotein composed of two - 
and two ß-subunits, linked together by disulfide bonds.  Insulin binds to the receptor’s extracellular 
α-subunit. Insulin binding presumably brings the two  α- subunits closer together (Figure 1).  This 
conformational change generate a chain of intracellular events such as, activation of the receptor 
tyrosine kinase, enhanced transport of glucose across the cell membrane, initiation of a series of 
phosphorylation de-phosphorylation reactions, eventually leading to stimulation of certain anabolic 
pathways through activation of certain enzymes [50]. Insulin binding also enables ATP binding to 
the ß-subunit’s intracellular domain. ATP binding activates receptor autophosphorylation which, in 
turn enables the receptor’s kinase activity toward intracellular protein substrates. There are 
numerous autophosphorylation sites in the ß-subunit’s intracellular domain. Three main clusters 
have been recognized to play a functionally important role. They include Y1158, Y1160, and Y1162 in 
the active loop of the catalytic domain, Y972 in the juxtamembrane domain, and Y1328 and Y 1334 in 
the carboxyl-terminal domain. Phosphorylation of residues in the active loop is essential to 
promote the receptor’s kinase activity. The activated receptors stimulate the activity of 
phospholipase C, which hydrolyzes specific glycosyl-      phosphoinositides localized in the plasma 
membrane. The generation of phosphor-inositolglycan and diacylglycerol causes selective 
stimulation of protein phosphatase, which dephosphorylates and either activates or inactivate 
intracellular enzymes involved in carbohydrates metabolism. The carboxyl-terminal 
phosphorylation sites may play a role in the receptor’s mitogenic activity. The juxta-membrane 
autophosphorylation site plays an important role in the interaction between the receptor and its 
intracellular substrates, providing a docking site to increase the stability of the receptor/substrate 
complex [51]. In addition to binding insulin, the insulin receptor can bind insulin-like growth 
factors (IGF-I and IGF-II) [52]. 
Insulin receptor substrate 1 (IRS-1) plays an important role in the insulin signaling cascade. 
Insulin, IGF-I, and certain cytokine receptors phosphorylate  IRSs at specific Y-x-x-M motifs, 
these motifs serve as molecular adhesives. Phosphorylation of their tyrosine residues increases the 
affinity with which IRS proteins bind other signaling molecules. Each tyrosine-phosphorylated 
motif binds to a specific signaling molecule. In this way, protein-protein complexes are formed, 
and various signaling pathways are engaged. The diversity of insulin action can potentially be 
explained by the activation of multiple signaling pathways [53].  These proteins include 
phosphatidyl 3-kinase (PI3-K) and growth factor receptor binding protein 2 (GRB-2). The IRS/PI 
3-K pathway leads to the generation of PIP3 and the consequent activation of PIP3-dependent 
kinases. The rapid increase in tris-phosphorylated inositol (PIP3) concentration in response to 
insulin stimulation activates several PIP3-dependent serine/threonine kinases, such as PI-dependent 
protein kinase-1 and -2, Akt (a product of the akt protooncogene), salt- and glucocorticoid-induced 
kinases, protein kinase C (PKC), Wortmannin-sensitive and insulin-stimulated serine kinase, and 
others [54]. Among the PIP3-dependent kinases, Akt has received much attention. Akt stimulates 
glucose uptake in 3T3-L1 adipocytes, phosphorylate proteins that regulate lipid synthesis, glycogen 
synthesis, cell survival and protein synthesis [55]. The enzyme PI 3-kinase catalyzes the addition 
of phosphate on the D3 position of the inositol ring of phospoinositol, leading to the generation of 
PI 3-phosphate. The enzyme is composed of a regulatory subunit, which exists in several isoforms 
(p85- , p85-ß, p55/AS53, p55PIK, and p50), and a catalytic 110-kDa subunit. 3-Phosphorylated 
inositides act as intracellular messengers, leading to activation of PI-dependent kinases, changes in 
intracellular trafficking, and growth stimulation. It stimulates glucose uptake, glycogen, lipid, and 
protein synthesis; and modulation of gene expression [56]. The GRB-2 link insulin signaling to the 
Ras pathway. The Ras/mitogen-activated protein kinase pathway can be activated by insulin 
through the formation of complexes between the exchange factors son-of-sevenless  (SOS) and 
growth factor receptor binding protein 2 (GRB2) and may play a role in certain tissues to stimulate 
the actions of insulin on growth and proliferation. Ultimately it activates glycogen synthetase, 
phosphorylase kinase and glycogen phosphorylase [51].  
 
1.6.5.1. Insulin receptor defect 
Receptor defect is due to a decrease in the number of insulin receptors or their biological function. 
This will lead to a rightward shift in the insulin dose – response curve, whereas there is no change 
in the maximal insulin action. This is called decrease in the sensitivity. This can be seen in subjects 
with impaired glucose tolerance and in patients with type 2 diabetes. Compared to normal persons 
binding of insulin to its receptors is already 20 % lower in overweight persons and 50 % lower in 
obese type 2 diabetic patients [12]. 
 
1.6.5.2 Post insulin receptor defects 
A pure post receptor defect in action affects the translation of the insulin signal into intracellular 
metabolic changes. This will lead to reduction in the biological affects at all insulin concentrations; 
this situation is termed a decrease in insulin responsiveness. In healthy individuals 40 % of the 
receptors are capable to autophosphorylate, while 60 % is not. In patients with type 2 only 14 % is 
capable to phosphorylate. Such disturbance may be caused by change in the structure of the beta 
subunit, or that serine residues are phosphorylated in preference, which will inhibit the addition of 
phosphate to tyrosine [12]. 
 
 
 
 
 
 
 
 
  
Figure 1: insulin receptor 
 
 
 
 
 
 
 
 
 
 1.6.6 Etiology of Type 2 Diabetes mellitus 
It is important to keep in mind that etiology of type 2 type diabetes is clearly multifactorial in 
origin, being determined by both genetic and environmental factors and still partially unknown.  
 
1.6.6.1. Genetic susceptibility for Type 2 Diabetes mellitus (T2DM): 
Diabetes mellitus is a geneticist's nightmare. Diabetes mellitus type 2 is a complex disorder 
characterized by both insulin resistance and relative insulin deficiency. The disease is common, but 
the nature of the primary defects and their molecular basis remains unknown for many reasons. 
Firstly type 2 DM is known as a heterogeneous disorder, with many possible causes. Secondly, it is 
still uncertain whether insulin resistance or insulin deficiency appears first [3]. It is well accepted 
that the insulin resistance of type 2 diabetes is partly genetically determined. The candidate gene 
approach has been used in the search for genes that may explain the presence or absence of 
diabetes. Candidate genes for diabetes are those suspected to play a role in the etiology of type 2 
diabetes or insulin resistance because the proteins they encode are involved in glucose regulation, 
either directly or indirectly. Variants in several genes have been evaluated for association with type 
2 diabetes. Although some have shown weak associations with diabetes, none has been identified 
as a major contributor to the common diabetes phenotype.  
Monogenic forms of type 2 DM with profound defect in insulin secretion include subtypes of 
maturity onset diabetes of the young (MODY), maternally inherited diabetes with deafness 
(MIDD) caused by mitochondrial mutations, and rare cases resulting from insulin gene mutations. 
The majority of proteins associated with MODY are transcription factors, such as hepatocyte 
nuclear factor- 4 alpha (HNF-4 alpha), HNF-1alpha, insulin promoter factor-1 (IPF-1), HNF-1beta, 
and NEUROD1. They influence expression of the other genes through regulation of mRNA 
synthesis. Only MODY2 form is associated with glucokinase, a key regulatory enzyme of the beta 
cell. There are striking differences in the clinical picture of MODY associated with glucokinase 
and MODY associated with transcription factors. Three monogenic forms of T2DM characterized 
by severe insulin resistance are the consequence of mutations in the PPARgamma, ATK2, and 
insulin receptor genes. Patients with monogenic T2DM, particularly with MODY, sometimes 
develop discrete extra-pancreatic phenotypes; for example, lipid abnormalities or a variety of 
cystic renal diseases [57].  MODY have been identified and classified into MODY1-6 according to 
the mutated genes that by being expressed in the pancreatic beta-cells confirm at the molecular 
level the clinical presentation of MODY as a predominantly insulin secretary deficient form of 
diabetes mellitus [58]. 
However, it is unlikely that a single gene can fully explain the presence or absence of typical type 
2 diabetes, because the trait is likely polygenic and multifactorial that is, it is caused by more than 
one gene as well as environmental factors [59].  Among the many candidate genes for diabetes is 
the  glucokinase, calpain 10 (CAPN10), the hepatic nuclear factor -4 alpha (HNF-4alpha) gene the 
upstream transcription  factor (USF1) which  is associated with familial combined hyperlipidaemia 
(FCHL), Peroxisome proliferator-activated receptor gamma (PPAR gamma),  and intestinal fatty 
acid binding protein (FABP2) gene [60].  
 
The Candidate genes:  
1. Glucokinase (GCK) 
Glucokinase is found in pancreatic ß- cells, hepatocytes, and specific bone regions. Expression is 
controlled by 2 tissue-specific promoters. Pancreatic glucokinase serves as the sensor for glucose, 
which regulates insulin secretion. Allosteric activators of glucokinase improve hepatic glucose 
metabolism and the pancreatic insulin response to glucose [61]. Heterozygous inactivating 
mutations in GCK cause maturity-onset diabetes of the young subtype 2, in which hyperglycemia 
is present from birth. The decreased expression (haploinsufficiency) of functional GCK seems to 
be the cause of the observed hyperglycemia among maturity-onset diabetes of the young subtype 2 
patients. The mechanism by which the –30G- A polymorphism causes hyperglycemia is uncertain.  
Mutations of the glucokinase gene account for 10% to 50% of the cases of maturity-onset. In 
patients with late-onset type 2 DM however, mutations of the glucokinase gene are rare, about 0.3 
% [62]. 
2. Fatty acid binding proteins (FABP) 
The FABP2 gene belongs to a family of more than 20 FABP genes that are expressed in a tissue-
specific manner. The FABP2 gene is expressed only in the absorptive simple columnar epithelial 
cells of the small intestine. In these cells, FABP2 transports hydrophobic fatty acids (FAs) from the 
plasma membrane, through the aqueous cytosol, to the endoplasmic reticulum (ER). In the ER, 
fatty acids are esterified with glycerol-3-phosphate (G3P) to form triglycerides (TGs). The TGs are 
packaged into chylomicrons that are transported into the circulation. The FABP2 gene is a 
candidate gene for insulin resistance because its product is involved in FA absorption and because 
defects in fatty ac regulation have been hypothesized to play a role in insulin resistance. The 
intestinal fatty acid binding protein (FABP2) gene is proposed as a candidate gene for diabetes 
because the protein it codes is involved in fatty acid (FA) absorption and metabolism and therefore 
may, affect insulin sensitivity and glucose metabolism [59]. 
3. Glucose transporters (GLUT): 
As glucose is not freely permeable across the lipid - bilayer membrane but it enter by facilitated 
diffusion. This process requires specific integral membrane proteins (glucose transporters) there 
are five known glucose transporter genes plus one pseudo gene in the family of facultative glucose 
transporters.  
The liver/islet (GLUT2) and muscle/adipose tissue (GLUT4) glucose-transporter gene 
products, membrane proteins that facilitate glucose uptake into cells, are important 
molecules for normal carbohydrate metabolism [63].  In the pancreas, GLUT2 regulates 
entry of glucose into the pancreatic cell and thus insulin secretion. SNPs of the SLC2A2 
gene (encoding GLUT2) have been associated with the risk of diabetes in some [36], but 
not in most of the studies [64]. 
4. Insulin receptor substrate 1(IRS-1): 
Insulin resistance in liver contributes greatly to the development of type 2 diabetes mellitus. 
Decreased hepatic insulin sensitivity leads to postprandial hyperglycemia and increased hepatic 
glucose production, which exacerbates an already deleterious situation of hyperglycemia and 
chronic hyperinsulinemia in diabetics. In addition to affecting glucose levels, hepatic insulin 
resistance may also lead to dysregulated lipid synthesis, which can lead to hepatic steatosis and 
further systemic insulin resistance. 
Hepatic insulin resistance may stem from compromised signaling through the insulin receptor 
substrate (IRS) proteins, a family of docking molecules that connect insulin receptor activation to 
essential downstream kinase cascades, such as the PI3K or MAPK pathways. The 2 major IRS 
isoforms, IRS-1 and IRS-2, are highly expressed in livers of normal but are down regulated to 
various extents in livers of diabetic. Since IRS proteins are a critical link in hepatic insulin 
signaling, it has been hypothesized that the decreased expression of IRS proteins in liver may be a 
key molecular lesion of hepatic insulin resistance [65]. The IRS-1 gene is located on chromosome 
2q36. The gene encoding insulin receptor substrate-1 (IRS1) represents a strong biological 
candidate for a contributory role in type 2 diabetes susceptibility. It was found that the combined 
prevalence of the two relatively infrequent no synonymous variants, P512A (sometimes called 
P513A, rs1801276) and G971R (G972R, rs1801278) increase susceptibility to type 2 diabetes [66]. 
5. Protein Tyrosine Phosphates 1B (PTP1B) 
In the Insulin receptor the PTPN1 gene codes for protein tyrosine phosphatase 1B (PTP1B), which 
negatively regulates insulin signaling by dephosphorylating the phosphotyrosine residues of the 
insulin receptor kinase activation segment. PTPN1 is located in 20q13, a genomic region linked to 
type 2 diabetes in multiple genetic studies. It was found that PTPN1 a significant contributor to 
type 2 diabetes susceptibility [67]. 
6. Calpain-10 (CAPN10) gene 
For the common form of type 2 DM in the general population, the calpain-10 (CAPN10) gene was 
the first T2DM candidate gene identified through genome wide linkage and positional cloning. 
CAPN10, located on chromosome 2q37.3, comprises 15 axons spanning 31 kb of genomic 
sequence that encodes a 672-amino-acid intracellular protease. Calpain-10 is primarily expressed 
in liver, skeletal muscle and pancreatic islets and is one of the nonlysosomal cysteine proteases 
essential for calcium-regulated intracellular signaling.  It was found that the G allele in the 
CAPN10 UCSNP-43 locus may have a modest effect on risk of T2DM in a recessive model and 
individuals homozygous for the common G allele had a statistically significant 19% higher risk of 
T2DM than carriers of the A allele [68].  
7. Hepatocyte Nuclear Factor – 1 α (HNF-1α) 
Hepatocyte nuclear factor 1α (HNF-1α) is an important transactivating  factor that is involved in 
pancreatic ß-cell glucose sensing because it increases transcription of many genes participating in 
the insulin secretion process. The G319S polymorphism of the TCF1 gene, encoding HNF-1α, has 
been associated with type 2 diabetes. However, there is no definite evidence that TCF1 is a major 
contributor to type 2 diabetes. HNF4-A constitutes a part of a network of transcription factors, 
including HNF-1α, controlling gene expression in pancreatic ß-cells and liver. Recent studies have 
indicated that SNPs in HNF4-A are associated with the risk of type 2 diabetes [69]. 
8. Incretins Glucagons -like polypeptide-1 (GLP-1),  
 Incretins, glucagons-like polypeptide-1 (GLP-1), and glucose-dependent insulinotropic 
polypeptide (GIP) are substances that are responsible for fast insulin response to ingested glucose. 
In patients with type 2 diabetes, the secretion of GLP-1 from intestinal mucosa and the 
responsiveness of the pancreatic ß-cells to GIP are diminished. No data on the association of SNPs 
of incretin hormones or their receptor genes, with the risk of type 2 diabetes are available   [64]. 
9. Acid phosphatase locus - 1 (ACP-1) 
Acid phosphatase locus- 1 (ACP-1) is a highly polymorphic enzyme that has an important role in 
flavoenzyme activity and in the control of insulin receptor activity and band 3 protein 
phosphorylation status. Adenosine deaminase (ADA) is a polymorphic enzyme that catalyses the 
irreversible deamination of adenosine to inosine and has an important role in regulating adenosine 
concentration. Based on the hypothesis that ACP-1 counteracts insulin signaling by 
dephosphorylating the insulin receptor and that adenosine has an anti-insulin action. Low ACP-1 
activity (low dephosphorylating action on insulin receptor) when associated with high ADA 
activity (low adenosine concentration) would result in a cumulative effect towards an increased 
glucose tolerance. On the contrary, high ACP-1 activity when associated with low ADA activity 
would result in a cumulative effect towards a decreased glucose tolerance. It was found that both 
ACP-1 and ADA contribute to the clinical manifestations of type 2 diabetes and probably also 
have a marginal influence on susceptibility to the disease [70]. 
 
1.6.6.2 Environmental Factors 
Body composition, Obesity, habitual physical activity (PA) levels, diet and smoking are factors 
that are at least partly environmentally determined, and all are known to exert their own substantial 
and independent effects on insulin resistance and type 2 diabetes. Environmental factors clearly 
must play a substantial role in determining type 2 diabetes prevalence, because type 2 diabetes has 
become dramatically more common in the last few decades. During this same time, factors such as 
habitual PA levels and body composition have changed substantially, while negligible genetic 
alterations could have occurred over this time frame [61]. 
A. Obesity 
The term obesity implies excess body fat, yet accurate measurement of body composition is not 
widely available in the clinical setting. Therefore, most clinical definitions of obesity rely on 
measures of body weight adjusted for height, such as the body mass index (BMI; in kg/m2). 
National population averages were once widely used to determine reference ranges. However, as 
obesity becomes more prevalent worldwide, there is a recognized need for standard definitions that 
are applicable across countries and over time. An expert panel compiled by the National Heart, 
Lung and Blood Institute (NHLBI) developed clinical guidelines that define overweight as a BMI 
of 25–29.9 kg/m2 and obesity as a BMI > 30 [71]. These cutoffs are consistent with those used by 
the World Health Organization, 1995 [72]. 
The prevalence of obesity is increasing among children and adolescents. Childhood obesity 
predicts young adult obesity, and young adult obesity predicts shortened lifespan. Obesity  has 
been associated with a large number of risk factors, including hypertension, hypercholesterolemia, 
hypertriglyceridemia, increased low-density lipoprotein (LDL)-cholesterol, increased very-low-
density lipoprotein (VLDL)-cholesterol, decreased high-density lipoprotein (HDL)-cholesterol, 
early atherosclerotic lesions [73].   
Many of the adverse health consequences of obesity are associated with alterations of 
carbohydrate and lipid metabolism. Hyperinsulinemia / insulin resistance is a risk factor 
for type 2 diabetes, and it is associated with increased blood pressure and adverse lipid 
profiles so weight loss improves insulin sensitivity. Fasting insulin and blood lipids serve 
both as direct indicators of subsequent risk and as biochemical markers of metabolically 
significant adiposity [74].  
There is a positive association of BMI with age, blood pressure, and cholesterol and a negative 
association with duration of diabetes, retinopathy, and use of insulin and this may explain why 
there is no strong relationship between BMI and mortality in type 2 diabetes mellitus. Weight loss, 
particularly in the relatively lean diabetic person, may be associated with an increased mortality 
risk [75]. 
In obesity and type 2 diabetes, insulin activation of lipoprotein lipase (LPL) in adipose tissue is 
delayed, and LPL activity in skeletal muscle is increased instead of decreased by hyperinsulinemia. 
The "scavenger" receptor CD36 has recently been identified as a fatty acid receptor/transporter, 
with particular abundance in adipose tissue, heart and skeletal muscle but with low expression in 
kidney and liver. A deficiency in CD36, a protein analogous to CD36/fatty acid transporter (FAT) 
in humans, has been reported to underlie the metabolic abnormalities of insulin-resistance and 
obesity [76]. 
B. Physical Activity 
Several clinical studies have shown that physical activity may result in reduced plasma insulin 
levels with improved insulin sensitivity and glucose intolerance in Type 2 DM and normal subjects 
[77]. It has been shown that regular physical activity (especially moderate activity) may be 
associated with a 50-60 % reduction in risk for Type 2DM [78]. It was suggested that training and 
physical fitness protect against glucose intolerance, whereas profound inactivity leads to 
worsening of glucose tolerance [79]. The prevalence of glucose intolerance was found to raise 
from 8 % in highly active subjects to 30 % in moderately active and 62 % in those with low 
activity levels. In most studies the effect of physical inactivity as a risk factor for Type 2DM, has 
been found to be independent of age, obesity, BMI, family history and gender [80]. 
C. Dietary Factors 
Although dietary factors have been considered important as possible determinant for Type 2 DM, 
no particular dietary element has been linked to this effect [81].  However, it has been suggested 
that obesity may mediate the effects of dietary factors, possibly through reduced physical activity. 
It has been shown that prior to onset, diabetic subjects consumed diets with high energy and fat 
contents and an inverse relationship was found between prevalence of diabetes and consumption of 
fiber rich diet [82]. 
D. Smoking 
It has been suggested that smoking may be associated with insulin resistance, hyperinsulinaemia 
and dyslipidemia [83]. Moreover, it has been found that among subjects with normal glucose 
tolerance, those who smoke have slightly higher HBA1c values than their counterparts. Observation 
has also indicated that in women heavy smoking,  may increase the risk for developing type 2 
diabetes mellitus  [84]. 
 
1.7 Etiology of Type 1 Diabetes Mellitus 
Type 1 (insulin-dependent) diabetes is due to the destruction of the insulin-secreting cells of the 
islets of Langerhans and is probably caused by environmental factors operating in a genetically 
susceptible host to initiate a destructive immune process. At diagnosis of classic type 1 diabetes, 
the islets are heavily infiltrated with lymphocytes and insulin secretion is absent or markedly 
reduced. The disease process tends to be slow and progressive such that patients have immune 
changes detectable many months, even years, before the clinical onset of type 1 diabetes.  
The most widely held view is that environmental factors induce this destructive immune response, 
which targets the insulin-secreting cells. An alternative view is that initially either the altered 
insulin secretion or insulin sensitivity is genetically determined, thereby predisposing to the 
destructive process. In support of this latter hypothesis, type 1 diabetes is associated with a 
polymorphism of the promoter region of the insulin gene and both decreased insulin secretion and 
decreased insulin sensitivity can be detected in the pre-diabetic period. Furthermore, changes in 
growth and weight are associated with risk of progression to diabetes.   It was found that the disease 
process causing type 1 diabetes is unlikely to be due to an inherited defect in either insulin 
secretion or insulin sensitivity, but the results do not exclude other factors that could accelerate the 
disease process or promote metabolic decompensation [85]. 
 
1.8 Long Term Diabetic Complications: 
The discovery and introduction of insulin in 1922 had prolonged the life span of most diabetics 
especially, insulin dependence diabetics. However, now there is enough time for the 
microvascular and macrovascular complications to develop.  Recent epidemiological studies of 
the long term complications of diabetes mellitus provided a new insight into the prevalence and 
incidence of these complications as well as into the complex interaction between the various 
complications and the risk factors. The complications that are specific for diabetes include 
retinopathy, neuropathy, microalbuminuria and overt nephropathy.  Patients with all form of 
diabetes of sufficient duration, including insulin dependent diabetes and non insulin dependent 
diabetes are vulnerable to these complications. Macrovascular complications, such as coronary 
heart disease, peripheral vascular disease and cerebrovascular accidents, though not specific for 
diabetes mellitus are more common among diabetic patients than in the general population [86].  
Diabetic complications are responsible for most of the morbidity and mortality of diabetes 
mellitus (DM) in African patients. Diabetic Africans are susceptible to long- term complications, 
but with lower prevalence rates than European and American population. Small vessels 
complications of nerves, kidneys, and eyes are more common than the large vessels in these 
populations. Although the relationship between glycemic control and the development of 
complications is not a simple one particularly for macro vascular disease, the vascular 
abnormalities appears to be due to long-standing metabolic derangement [32]. 
 
 
 
1.8.1 Pattern of Long Term Diabetic Complications 
The prevalence of diabetic complications varies greatly depending on the criteria used for 
detection and the population of patients studied. Recommendation for the standardization of 
methods of detection and definitions of diabetes related complications in epidemiological studies 
have been proposed [87]. The WHO Multinational Study has reported a wide range of variation 
in the prevalence of vascular complications among 14 countries world wide [88]. Unfortunately 
none of the African countries was represented in the WHO multinational Study.  Most studies on 
the pattern of long term complications of diabetes on the African continent were cross sectional 
hospital based studies, and only a few have provided follow up reports [89]. Comparison of the 
prevalence rates reported from different African countries is difficult, owing to the heterogeneity 
of cohorts regarding the type of diabetes, as well as to the use of different methods of detection 
of complications and the wide range of the duration of diabetes. 
Major ethnic differences have been observed in the prevalence of diabetic complications in type 
2DM. European diabetic patients diagnosed after the age of 40 years showed an overall 
prevalence of proteinuria of around 16 % [90].  Proteinuria in type 2 diabetes was detected in 
53.1 % in Cameron [22], 49.2 % in Nigeria [91], in 33 % in Netherlands [92],  in Nairobi 26 % 
[93], in Senegal 15.7 % [94], and the lowest prevalence 13.4%, in Hong Kong [95]. Data from 
the United States has shown that the prevalence of diabetic retinopathy increased from 6.9 % to 
17.4 % between the years 1991 and 1999. Now it accounts for 39 % [96]. In Africa there is 
ample evidence that the prevalence of retinopathy of all types ranges from 15 to 50% [97].  
Hypertension and macrovascular complications were reported to be rare among indigenous 
African population. However recent studies have indicated that macrovascular complications 
may be more prevalent than previously thought.   
In Sudan, diabetes is associated with severe morbidity and mortality rates. The vast majorities of 
Sudanese diabetic patients are poorly controlled and more prone to both micro vascular and 
macro vascular complications than previously reported and have higher rates of acute metabolic 
complications, which are a main cause of death [98]. The overall prevalence of diabetic 
complications reported by El Mahdi, 1991 [99], were as follows: Neuropathy (31.5%), 
retinopathy (17.4%), cataract (16%), Nephropathy (9.2%), coronary heart disease (5.1%), 
cerebrovascular disease (4.4%), and peripheral vascular disease (3.4 %). 
 
A.  Diabetic Retinopathy 
Diabetic retinopathy (DR) is a sight - threatening chronic complication of diabetes mellitus and 
is the leading cause of acquired blindness in adults, as reported by the American Diabetes 
Association. The natural history of retinopathy in type 2DM is more difficult to delineate since 
type 2DM may be present for many years before it is diagnosed. Up to 21% of patients with type 
2 DM have retinopathy at time of first diagnosis of diabetes, and most develop some degree of 
retinopathy over time [100]. Risk factors for development and progression of diabetic 
retinopathy include among others, hyperglycemia, duration of diabetes, hypertension, smoking, 
race and genetic factors [101]. 
As with all diabetes specific complications, the development of retinopathy depends on the 
duration of the disease. The first and the most visible lesions are small diameter, <100 µm 
microaneurysms arising from the terminal capillaries of the retina. These signs are present in 
nearly all persons who have had type 1 diabetes for 20 years, and in nearly 80 percent of those 
with type 2 disease of this duration. Dots and blot hemorrhages appear when erythrocytes escape 
from the microaneurysms. The retinal vessels are abnormally permeable and leak serous fluid, 
leading to the formation of hard exudates. Microanerysms, dots, blot hemorrhages and hard 
exudates are described as "background" retinopathy, (because of their common occurrence in 
diabetes) or preferably, non-proliferative retinopathy. Unless, non –proliferative retinopathy 
occurs near the maculae and causes macular oedema, it does not lead to loss of vision. Macular 
oedema, occurs when leakage of fluid from abnormal vessels near the maculae disrupt the light 
path to the maculae and result in loss of visual acuity. With increasingly severe retinopathy, the 
abnormal vessels can become occluded, leading to retinal ischemia with infarctions in the nerve 
layer of the retina, seen as soft "cotton wool", exudates (Preproliferative retinopathy). In 
response to ischemia new vessels develop (neovascularization). The new vessels proliferate out 
of the retinal surface and into the vitreous cavity (proliferative retinopathy). They are attenuated 
and fragile and tend to bleed into the vitreous. The vitreous hemorrhages can obscure vision, but 
they are usually reabsorbed in one to three months. Subsequent fibroproliferative changes result 
in retinal traction, detachment and loss of vision. Nonproliferative retinopathy and proliferative 
retinopathy are the characteristic lesions of diabetic retinopathy. Patients with diabetes are also at 
higher risk for other ophthalmic disease, such as cataracts [86].  
B. Diabetic Nephropathy: 
Nephropathy is the diabetes-specific complication associated with the greatest mortality. 
Although the vast majority of patients have some degree of retinopathy, nephropathy develops in 
only 35 to 45 percent of patients with type1 DM and in less than 20 % of those with type 2DM. 
The exact prevalence of nephropathy in Type 2DM is difficult due to the uncertain duration of 
the disease and the high prevalence of coexisting hypertension, which may cause nephrosclerosis 
as 10% of type 2 diabetes patients usually present with persistent microalbuminuria at diagnosis, 
and 50-60% are already hypertensive [102]. Slight increased urinary excretion of albumin is 
predictive of clinical nephropathy. Such an increase in albumin excretion is not measurable by 
the test ordinarily used to detect proteinuria and has been termed "microalbuminuria". 
Microalbumin is not a tiny albumin molecule. The term "microalbuminuria" denotes the urinary 
excretion of albumin at concentrations above the expected for normal individuals but below what 
was typically detected as an overt protenuria by standard calorimetric or screening methods (i.e. 
15-200 µg/min or 30 -300 mg/24h or by using a random spot urine collection, and measuring the 
albumin- creatinine ratio [103]. It may be an expression of an early phase of diabetic renal 
disease, also called "incipient diabetic nephropathy", but a number of other potential causes of 
microalbuminuria e.g. exercise, poor diabetic control, and non diabetic renal or systemic 
diseases, including hypertension should be considered.  Micoalbuminuria is not only related to 
diagnosis, but it is also important to early intervention, e.g., optimized diabetes care, and more 
specifically to early antihypertensive treatment [104]. 
Microalbuminuria appears to precede nephropathy in patients with type 2DM, as in those with  
type 1DM. Initially there is renal hypertrophy, with expansion of the glomeruli, including the 
mesangium and the glomerular basement membrane, and an increase in kidney size. The 
glomerular composition changes more slowly, leading to characteristic mesangial expansion, 
thickening of the glomerular basement membrane, afferent and efferent arterioles. With more 
advanced nephropathy (progressive proteinuria), glomerular occlusion occurs. There is 
compensatory hypertrophy of the functioning glomeruli during the disease. Klimmelsteil-Wilson 
nodular glomerulosclerosis is a relatively late phenomenon that affects a minority of patients 
with nephropathy. End stage renal disease is characterized by small, atrophic kidneys with 
diffuse glomeruolsclerosis [86]. 
In diabetic patients, several factors characterize the increase of the risk in developing renal 
damage.  They can be distinguished as: Diabetes-related factors (duration of diabetes and age of 
subjects affected,  hypertension, proteinuria, inadequate glycemic control and tissue hypoxia, 
genetic factors familial and racial factors, familial albuminuria clustering in whites and African 
Americans with type 2 diabetes mellitus, familial hypertension and cardiovascular disease 
clustering, ACE gene polymorphism and familial hypertension); other factors (dyslipidemia, 
obesity  and smoking) have all been described as risk factors for the development and the 
progression of diabetic nephropathy 
  
.  
 
 Some factors have been identified to be associated with a high risk of nephropathy: elevated 
blood pressure, glycosylated hemoglobin, cholesterol concentrations, smoking, advanced age, 
high level of insulin resistance, male sex (the risk is lower among women, at least before 
menopause), black or Native American race, and possibly high protein intake [105]. 
C. Diabetic Neuropathy: 
A peripheral symmetric sensorimotor neuropathy is the most common form of diabetic 
neuropathy,  whose other forms include cranial and peripheral motor neuropathies and 
autonomic neuropathies. Although neuropathy is also more common with a longer duration of 
diabetes, a relatively severe, early onset polyneuropathy has been described [86]. 
Distal symmetrical neuropathy of a clinically significant degree probably affects 20-30% of 
diabetic patients.  Its symptoms include parathesia, which characteristically worsen at night. Its 
prevalence rises with increasing duration and other associations include smoking, increasing 
height and microalbuminuria [3]. 
A minority of patients have painful peripheral neuropathy with lacinating or burning dysesthesia, 
severe enough in some to be associated with depression and anorexia [106]. Pathological features 
of diabetic peripheral neuropathy include distal axonal loss with fall out of large (mylinated) and 
small fibers, focal demyelination and regeneration. Functional abnormalities include slowing of 
conduction velocity, rises in sensory modality threshold and slowing of axonal transport [3]. 
Focal motor (cranial and peripheral) and compression neuropathies and mononeuritis multiplex 
are less common than the sensorimotor neuropathies. 
Radiculopathies may also occur, mimicking disk disease. Autonomic neuropathy can affect 
gastric or intestinal motility, erectile function, bladder function, cardiac function, and vascular 
tone. Gastroparesis may not only cause symptoms but also alter the absorption of meals and 
make glycaemic control problematic. Diabetic diarrhea and incontinence is rare, but can be 
disabling. Impotence is the most common clinical manifestation of autonomic neuropathy 
affecting more than 50% of men with diabetes. Cardiac autonomic neuropathy may result in 
resting tachycardia and postural hypotension [3]. 
D. Macrovascular (Cardiovascular disease) complications: 
The macrovascular complications of diabetes head the list of complications in causing morbidity, 
mortality, and health care expenditures. Roughly 40% of total mortality in persons with diabetes 
is caused by ischemic heart disease, with other categories of cardiovascular disease (CVD), 
including stroke, accounting for an additional 25%. The next leading cause of death in persons 
with diabetes, malignant neoplasm, causes only 13% of total deaths. In general, the risk of 
cardiovascular mortality is from 2 to 4 times higher in persons with diabetes than in persons 
without diabetes.  Diabetes increases cardiovascular risk more in women than in men, thereby 
eliminating either wholly or in part, the female protection against coronary disease that is 
observed in the general population.  In addition, coronary artery disease develops at a younger 
age in diabetic patients than in non diabetic patients, especially if renal disease supervenes [107]. 
Although asymptomatic coronary artery disease and myocardial infarction are probably not 
much more common in diabetic patients than in non diabetic patients, atypical angina symptoms, 
including symptoms of congestive heart failure, are a more common clinical presentation of 
coronary artery disease in those with diabetes. Mortality from first or subsequent myocardial 
infarction is higher in diabetic than in non diabetics. The increased cardiovascular risk associated 
with diabetes is not merely the result of increased levels of conventional cardiovascular risk 
factors, e.g., dyslipidemia, hypertension, and obesity. However, independently of these variables, 
diabetes remains a major risk factor for coronary artery disease [86]. 
 
1.8.2. Risk factors for diabetic complications: 
1.8.2.1. Hyperglycemia: 
All forms of diabetes are characterized by chronic hyperglycemia associated with the 
development of diabetic complications. There is a durable relation between the level of glucose 
control and the prevalence and incidence of retinopathy, nephropathy and neuropathy. Early in 
the course of diabetes, intracellular hyperglycemia causes abnormalities in blood flow and 
increased vascular permeability. This reflects decreased activity of vasodilators such as nitric 
oxide, increased activity of vasoconstrictors such as angiotensin II and endothelin-1, and 
elaboration of permeability factors such as vascular endothelial growth factor (VEGF).  
Quantative and qualitative abnormalities of extra cellular matrix contribute to an irreversible 
increase in vascular permeability. With time, micro vascular cell loss occurs, in part as a result of 
programmed cell death, and progressive capillary occlusion due both to extra cellular matrix 
overproduction induced by growth factors such as transforming growth factor - β (TG-β), and to 
deposition of extravasated periodic acid- Schiff- positive plasma proteins. 
Hyperglycemia may also decrease production of trophic factors for endothelial and neuronal 
cells. Together these changes lead to oedema, ischemia and hypoxia- induced neovascularization 
in the retina, proteinuria, mesangial matrix expansion and glomerulosclerosis in the kidney, and 
multifocal axonal degeneration in peripheral nerves [108]. Hyperglycemias itself also inhibits 
production of nitric oxide in arterial endothelial cells and stimulate production of plasminogn 
activating inhibitor-1 (PAI-1). Hyperglycemia may represent a causal factor for in vivo platelet 
activation, and may be responsible for nonenzymatic glycation of platelet glycoprotein, causing 
changes in their structure and conformation, as well as alterations of membrane lipid dynamics. 
Furthermore, hyperglycemia-induced oxidative stress is responsible for enhanced peroxidation of 
arachidonic acid to form biologically active isoprostanes, which represents an important 
biochemical link between impaired glycemic control and persistent platelet activation. Finally, 
increased oxidative stress is responsible for activation of transcription factors and expression of 
redox-sensitive genes leading to a phenotypic switch of endothelium toward an adhesive, pro-
thrombotic condition, initial platelet activation, adhesion and subsequent platelet aggregate 
formation [109]. 
Hyperglycemia is associated with glycosylation of virtually every protein in the body. Many of 
these biochemical changes could contribute to atherogenesis. For example, advanced glycation 
end products induce excessive cross-linking of collagen and other extracellular matrix proteins in 
many tissues, including the vascular wall. This excessive cross-linking causes covalent trapping 
of LDLs, which may then accumulate in vascular walls. In addition, apolipoprotein B, a 
component of LDL, can be modified by advanced glycation end products. Such advanced 
glycation end product–modified LDL has been shown to have a prolonged half-life, which, 
combined with trapping of the lipoprotein in vascular walls, could lead to increased oxidation of 
LDL Oxidative modification of LDL alters its biological properties, resulting in chemotaxis of 
monocytes or T lymphocytes in addition to the modulation of growth factors and cytokine 
production from endothelial cells, smooth muscle cells, and macrophages. Furthermore, 
cytotoxicity of Ox LDL from cultured endothelial cells has been clearly demonstrated to be 
atherogenic [110]. 
1.8.2.2. Hypertension: 
Diabetes and hypertension are interrelated diseases that strongly predispose the individual to 
atherosclerotic cardiovascular disease. Hypertension is about twice as frequent in individuals 
with diabetes as in those without. Life style and genetic factors are important factors contributing 
to both diabetes mellitus and hypertension. The prevalence of coexisting hypertension and 
diabetes appears to be increasing in industrialized nations because populations are ageing, and 
both diabetes mellitus and hypertension increase with age [111].  
It is estimated that 35-75 % of diabetic cardiovascular and renal complications can be attributed 
to hypertension. Hypertension also contributes to diabetic retinopathy, which is the leading cause 
of the newly diagnosed blindness in the United States [112].  
Essential hypertension accounts for the majority of hypertension in individuals with diabetes, 
particularly those with  type 2DM, who constitute more than 90% of people with a dual 
diagnosis of diabetes and hypertension. Hypertension often antedates and likely contributes to 
the development of nephropathy in many diabetic individuals. Diabetic nephropathy, which 
occurs after 15 years in 20% of those with type 2DM, is an important contributing factor to the 
development of hypertension in diabetic individual [113].   
It had been found that several mechanisms acting in concert in mediating the pathogenesis of 
vascular disease in the diabetic hypertensive patients.  Some of the more important mechanisms 
of cardiovascular and renal injury associated with diabetes mellitus are, platelet adhesion and 
platelet aggregation, Coagulation abnormalities, lipoprotein abnormalities, insulin-like growth 
factor-1 and vascular contractility and the role of hyperglycemia in mediating the vascular 
abnormalities associated with diabetes and hypertension [114]. 
1.8.2.3. Smoking: 
Cigarette smoking increases this risk for diabetic nephropathy, retinopathy, and 
neuropathy, probably via its metabolic effects in combination with increased inflammation 
and endothelial dysfunction. The increased risk for macrovascular complications, 
coronary heart disease (CHD), stroke, and peripheral vascular disease, is most 
pronounced in type 2 diabetic patients. Smoking cessation is of utmost importance to 
facilitate glycemic control and limit the development of diabetic complications [115]. 
Cigarette smoking, type II diabetes mellitus, and arterial hypertension increase the risk of 
atherosclerosis and premature cardiovascular diseases. Since the endothelium of conduit 
and resistance vessels is the target for many lesions, early endothelial dysfunction in 
these conditions has been shown to result in atherosclerosis Smoking-induced 
impairment of endothelium-dependent vasodilatation is most probably related to a 
decreased availability of nitrous oxide (NO).  Endothelial dysfunction in smokers with 
normal vascular smooth-muscle cell reactivity is related to the toxic effects of nicotine, 
carbon monoxide, and oxygen that may increase oxidative stress and decrease the 
availability of NO.  Nicotine can also affect the expression of adhesion molecules and 
monocyte migration through the formation of cyclooxygenase-dependent endothelium-
derived contraction factors (mainly TX), and can alter DNA synthesis/ repair, cell 
proliferation, and cytotoxicity [116]. 
Smoking has been pinpointed as a factor causing progression of chronic nephropathies. It is worth 
noting that smoking increases urinary albumin concentration, even at albumin concentrations 
below that of microalbuminuria. There is growing evidence that smoking not only increases the 
risk of albuminuria but also decreases the GFR and increases the risk of renal functional 
deterioration and the progression of renal failure. The frequency of nephropathy is progressively 
higher with increasing cigarette consumption. Cigarette smoking in patients with kidney disease, 
including diabetic nephropathy, is associated with myointimal hyperplasia of intrarenal arteries, 
and there is a trend toward arteriolar hyalinosis in smokers. The renal vessels are the main targets 
of cigarette smoke in the kidney. In addition, smoke damages endothelial cells, and nicotine 
induces smooth muscle cell proliferation. Smoking may be associated with podocyte injuries in 
patients with early diabetic nephropathy [117]. 
 
1.9 The Acute Phase Reactant Proteins (APRPs) and their functions 
The acute phase of inflammatory response refers to a wide range of physiological changes that are 
initiated immediately after an infection or a physical trauma has occurred [118]. 
The acute phase response, which involves at least 20 of the plasma proteins, is characterized by 
fever, change in vascular permeability, metabolic and catabolic profiles of many organs [119]. The 
response is initiated and coordinated by a large number of diverse inflammatory mediators, include 
cytokines, anaphylotoxins and glucocorticoids. Some of these are released initially at the site of 
inflammation by activated mononuclear phagocytes, lymphocytes or other differentiated cell types 
and have potent local and systemic effects. The ensuing cascade of mediators induced activation, 
proliferation, altered behavior and changes in biosynthetic capacity of variety of targets cells and 
tissues. This enhances host survival by neutralizing the inflammatory agent by promoting repair 
process, thus initiating a return to normal function [118]. 
An important aspect of the acute phase response is radically altered biosynthetic profile of the 
liver. Under normal circumstances, the liver synthesizes a characteristic range of plasma proteins 
at steady state concentrations. Many of the proteins have important functions and higher plasma 
levels of these acute phase reactants (APRs) are required during the acute phase response 
following the inflammatory stimulus. Although most APRs are synthesized by hepatocytes, there 
are other cell types including monocytes, endothelial cells, fibroblasts and adipocytes synthesize 
some of these APRs. 
 Many soluble factors initiate and maintain an inflammatory response including several hormones, 
which specifically regulate the transcription of human APRs .  
These include interleukin 1 (IL-1), IL-6, Tumor necrosis factor- alpha (TNF-α), Leukemia 
inhibitory factor (LIF), interferon gamma (IFN-γ), glucocorticoids and IL-11 [118, 120]. In 
addition, Insulin modulation of acute –phase protein production in a human hepatoma cell line 
have been shown to act as inhibitors of cytokine-driven inductions of some APRs [121].  
An important feature of the acute phase response is  that IL-1 and TNF-α stimulate ,via the central 
nervous system (CNS), the synthesis of glucocortcoids by the adrenal glands, which results in co-
operative enhancement of the IL-1 and TNF-α mediated induction of the APRs synthesis in the  
liver. This effect is coincident with the glucocorticoid - mediated down regulation of IL-1 
synthesis by macrophages, thereby creating a negative-feedback loop between the immune system 
and CNS to reduce de novo cytokine synthesis [118]. Some inflammatory- sensitive plasma 
proteins such as fibrinogen, orsomucoid,  α 1- antitrypsin, haptoglobin and ceruloplasmin are 
associated with the development of diabetes mellitus [122]. 
 
1.10     Haptoglobin: 
1.10.1   Haptoglobin Definition: 
Human plasma haptoglobin (Hp), is an α 2 sialoglycoprotein, it represent 1.3 % of total plasma 
protein. It is synthesized and metabolized also in the liver. It is considered as one of the 
inflammation - sensitive plasma proteins. 
 
 
1.10.2 Molecular Structure and Genetics of haptoglobin 
Haptoglobin (Hp) is characterized by molecular heterogeneity, with three major phenotypes: Hp 1-
1, Hp 2-2, and the heterozygous 2-1, [Figure 1.2]. The Hp phenotypes 1-1, 2-1 and 2-2 are 
attributed to the two common alleles, 1, and 2, located at chromosome 16q22.1 [123]. The genetic 
variants are transmitted with an autosomal codominant mode of inheritance. They are widely used 
as genetic markers in human genetics and forensic medicine [124]. 
Hp consist of two different polypeptides chains, the α chain and the β chain. Structurally, the 
minimal unit of Hp (β -α - α - β) is joined by disulfide linkage of the two variant α chains and the 
two identical β chains [123].  The β chain (40 k Da) is heavier than the α chain and is identical in 
all Hp types. There are three α chains: α 1S (S= slower), α 1F (F=faster), and the slow migrating α2 –
chains. The Hp polymorphism arise from variants α chains. The Hp 1-1 phenotype expresses only 
α 1 chain, with formula (α 1 β) 2. The heterozygote 2-1, [(α 1 β) 2 + (α2 β) n] is characterized by 
polymerization. Hp 2-2 comprises higher molecular mass, with (α2 β) n formula, [Figure 1.3]. The 
Hp α2 exists only in humans. The hemoglobin (Hb) binding capacity of Hp is attributed to Hp β 
chain [125].  
 
  
 
 
 
 
 
 
 
 
 
Figure 1.2:   Electrophoresis patterns of Hp phenotypes 1-1, 2-1 and 2-2 on 
polyacrylamide gel electrophoresis using Benzidine stain 
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Figure 1.3: Structural Differences Between haptoglobin Phenotypes 
 
 
 
 
 
 
 
 
The Hp gene is expressed in hepatocytes. Synthesis of Hp is considerably lower in fetal than adult 
liver due to difference in the transcriptional rate [126].  Expression of the Hp gene is absent in 
''anhaptoglbinemia'' (Hp 0-0 phenotype), a condition present in nearly 1 in 1000 Caucasian, but it 
is more common in blacks especially of West Africa (Nigeria & Cameron) as it represent >30 
[127]. 
The hepatic synthesis of Hp is induced by cytokines, such as interlukin-6 (IL-6). IL-1 and tumor 
necrosis factor (TNF). The physiological half life of plasma Hp is estimated as 4-5 days [126]. 
1.10.3  Geographical distribution: 
The gene frequency of Hp showed marked geographical differences, with the lowest Hp1 gene in 
Southeast Asia and the greatest frequency in Africa and South America. The phenotype 
distribution in European population shows that ~16 % of individuals are Hp1-1, 48 % Hp 2-1, and 
36 % Hp 2-2,  [128], while in African (Nigerian), Hp 1-1 represent 53.5 %, Hp 2-1,  11.1 % , 2-2 
only ~ 3 %, while Hp 0-0, 32% [125]. In Sudanese population the Hp phenotype distribution 
shows that 26 % were Hp1-1, 55%, Hp 2-1 and 18.3 % Hp 2-2 [129]. (Table 1.2). 
 
Table 1.2: The Geographical distribution of Hp phenotypes 
 
 
Population Hp 1-1 Hp2-1 Hp 2-2 
Americans 14.4 % 48.2 % 37.4% 
European     (France) 15.3% 49.7% 35% 
India 2.5% 13.3% 84.2% 
Japan 7.4% 37.2% 35.4% 
Nigeria 53.5% 11.1% 3.0% 
Burundi 28.2% 47.7% 22.1% 
Sudan 26% 55.8% 18.3% 
 
 
  
 
 
1.10.4   Haptoglobin and CD 163 Receptor 
CD 163 is a highly expressed macrophage membrane protein belonging to the scavenger 
receptor cysteine rich (SRCR) domain family. It is 130-kDa protein belonging to a group of 
proteins constituting a subfamily of scavenge receptor cysteine-rich (SRCR) domain 
proteins. These proteins, including CD5, CD6, CD163, CD163b, and WC1, are membrane 
proteins with a short cytoplasmic tail, a transmembrane segment, and an extracellular 
domain consisting exclusively of a variant number of consecutive class B SRCR domains.  
CD163 is the only protein of the class B SRCR domain protein subfamily identified as a 
receptor for an extracellular ligand [130]. The CD163 expression is induced by interleukin-
6, interleukin-10 and glucocorticoids. Its function remained unknown until recently when 
CD163 was identified as the endocytic receptor binding hemoglobin in complex with the 
plasma protein haptoglobin.   It binds with high affinity to the Hp-Hb complex that instantly 
forms in plasma when Hb is released from ruptured erythrocytes and is exposed to 
plasma Hp (0.3-2 g/liter).  This captor-receptor system controlling the metabolic route of 
Hb during limited hemolysis thereby protects against heme-mediated oxidative damages, 
in particular in the kidneys that readily filtrate non-complexed Hb and take up Hb in the 
proximal tubules. CD163 has no affinity for noncomplexed Hp or Hb. This Hp-Hb complex-
specific recognition by CD163 explains the decrease in Hp concentration in plasma during 
accelerated hemolysis. CD163 – mediated endocytosis represents a major pathway for 
the uptake of iron in tissue macrophages [131]. [Figure 1.4]. 
  After endocytosis, iron can be released from Hb catalyzed by heme oxygenase and is 
either sequestered in ferritin or mobilized to extracellular space. Both haem oxygenase 
and ferritin are known to be produced at high levels in alveolar macrophages and up 
regulated during inflammation [132]. Besides having a role in clearance of Hb from 
plasma, CD163 is suggested to have an immunomodulatory role. Two distinct 
mechanisms may account for this. First, clearance of the hemoglobin results in 
conversion of the heme molecule to CO, bilirubin, and Fe, which overall are suggested to 
have an anti-inflammatory effect. Second, ligand binding to CD163 is reported to induce 
tyrosine kinase - and calcium-dependent signaling and increased secretion of IL-6 and IL-
10 [130]. Complexes of hemoglobin and multimeric Hp (the 2–2 phenotype) exhibit higher 
functional affinity for CD163 than do complexes of hemoglobin and dimeric Hp (the 1–1 
phenotype). These functional differences between the various Hp types have important 
biological and clinical consequences [133]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.4: Hp and CD 163 Receptor 
  
 
 
 
 
 
 
1.10.5   Functional properties of Hp: [Table 1.3] 
Hemoglobin (Hb) is the most abundant and functionally important protein in erythrocytes. 
However once it is released from red blood cells, it become highly toxic because of the oxidative 
nature of iron-containing heme, which participate in Fenton reaction to produce reactive oxygen 
species which cause cell injury [134]. 
1. Binding Hemoglobin  
Normally in humans, about 1 mg of iron is absorbed daily by the intestine, and at the same time, an 
approximately equal amount is eliminated from the body. Remarkably, this dietary iron accounts 
for only 1 to 3% of the iron that is supplied daily to the blood. Most of the iron requirement is 
provided through reutilization from existing total body stores of 3 to 4 g, of which about 70% is 
maintained within hemoglobin. From these facts, it is clear that heme-iron metabolism constitutes a 
major component of iron homeostasis. Hp is the plasma protein with the highest binding affinity 
for hemoglobin. Release of hemoglobin into plasma is a physiological phenomenon associated with 
intravascular hemolysis occurring during destruction of senescent erythrocytes and enucleating of 
erythroblasts. However, intravascular hemolysis becomes a severe pathological complication when 
it is accelerated in various autoimmune, infectious (such as malaria) and inherited (such as sickle 
cell disease) disorders. In plasma, stable Hp-hemoglobin complexes are formed and these are 
subsequently delivered to the reticuloendothelial system by CD163 receptor-mediated endocytosis. 
In this way, Hp is believed to reduce loss of hemoglobin through the glomeruli, hence protecting 
against peroxidative kidney injury, and allowing heme-iron recycling [133]. 
2. Inhibition of Nitric Oxide (NO). 
Nitric oxide is a soluble, free radical gas, highly reactive, produced by several types of human cells 
and has different functions. In the central nervous system it regulates neurotransmitter release, in 
macrophages act as cytotoxic metabolites for killing microbes and tumor cells. NO has been 
identified as the endothelium derived relaxing factor (EDRF). Large amounts of NO are cytotoxic 
and are associated with non specific defense against microorganisms. Free Hb inhibits 
endothelium-dependent vasodilatation by means of a direct chemical interaction with EDRF. In 
presence of haptoglobin, EDRF has no intravascular effect, and that its physiological role is that of 
a local vasodilator [135]. 
3. Antioxidant 
Free radicals such as superoxide (O2-) and hydroxyl (OH) are extremely reactive molecules that 
can cause cell damage by peroxidation of membrane lipids. Free Hb promotes the accumulation of 
hydroxyl radicals because iron can generate OH by means of Fenton reaction:     
                          H2O2 + Fe2+ → Fe3 + OH - + OH. 
 Heme iron catalyzes the oxidation of low density lipoproteins, which can damage vascular 
endothelial cells [126].  This damage is reduced by HP-Hb binding capacity. However, Hp- Hb 
binding is phenotype dependent. Hp 1-1 is superior to Hp 2-1 and 2-2 in binding to Hb. The 
diversity in antioxidant activity of Hp phenotype may explain, in part the clinical outcome by 
which Hp phenotype is associated with different susceptibility to free radical related 
atherosclerosis and auto immune disorders [123]. 
4. Inhibition of Prostaglandin synthesis: 
Hp is an endogenous inhibitor for prostaglandin synthesis as a consequence of Hp- Hb binding; the 
heme compounds that catalyze the oxidation of arachidonic acid by prostaglandin synthase are 
removed. The inhibitory effect of Hp has important biological and anti-inflammatory 
consequences. The inhibitory effects of Hp 2-2 and Hp 2-1 on prostaglandin synthesis are less 
pronounced than that of Hp 1-1 [136]. 
5. Bacteriostatic effect: 
As a consequence of the capture of free Hb by Hp, heme iron is unavailable for bacterial growth. 
An iron - free environment established by Hp is part of the non specific defense against bacterial 
invasion [137]. It was found that haptoglobin acts as a potent immunosuppressor of lymphocyte 
function and modulates the helper T-cell type 1 and type 2 (Th1/Th2) balance within the body 
[138]. 
6. Angiogenesis 
Angiogenesis plays an important role in a variety of physiological and pathological conditions, 
including tumors growth, wound healing and chronic inflammatory diseases. Hp has been 
identified as one of the serum angiogenic factors required for proliferation and differentiation of 
endothelial cells in the formation of new blood vessels. Hp 2-2 is more angiogenic than the other 
phenotypes [139]. 
 
 
 
Table 1.3:  The physical and functional properties of Hp Phenotypes [125]. 
 
Character HP 1-1 Hp  2-1 Hp 2-2 
Structural formula (α 1 β) 2 { (α 1 β) 2 + (α2 β) n} (α2 β) n 
Molecular mass, kDa 86 86 -300 170 -900 
Hemoglobin binding Strong intermediate weak 
Antioxidative capacity Strong intermediate weak 
Inhibition of prostaglandin 
synthesis 
Strong intermediate weak 
Angiogenic effect Weak intermediate Strong 
Agglutination of 
Streptococcus Pyogens T4 
----- intermediate Strong 
Affinity towards CD22 Strong Strong Strong 
 
 
 
 
 
 
 
1.10.6  Haptoglobin as a Diseases Marker  
    Hp behaves like an acute-phase protein, its plasma concentration increase in response to a 
variety of stimuli e.g. infections, neoplasia, pregnancy, trauma, acute myocardial infarction. 
Hyperhaptoglobinemia is also observed in inflammatory psychiatric disorders, such as major 
depression. The relationship between Hp phenotype and   different diseases is shown in (Table 4). 
 
 
Table 1.4: Clinical consequences of Hp polymorphism 
 
  
 
 
 
 
 
 
 
 
1.10.6.1 Haptoglobin and Diabetes 
There exists a growing body of evidence that diabetic vascular disease develops only in those 
patients who are genetically susceptible. As an acute-phase reactant Hp may be functionally 
involved in the etiology of DM which is associated with  immunologic and inflammatory 
processes, [140]. 
Hp circulates in plasma as a polymer whose stoichiometry and biophysical properties are Hp 
genotype dependent (hereafter referred to as Hp 1-1, Hp 2-1, or Hp 2-2 protein). All three types of 
Hp protein (Hp 1-1, Hp 2-1, and Hp 2-2) bind free hemoglobin (Hb) equally well with high 
affinity, thereby serving to prevent iron loss and protecting tissues from Hb-induced oxidative 
damage. Hp also seems to have immunomodulatory functions intimately related to its Hb binding 
function, because the Hp-Hb complex binds with high affinity to the CD163 scavenger receptor 
Disease Clinical consequence of Hp polymorphism 
Tuberculosis Hp 2-2 overrepresented among patients with advanced destruction. 
HIV Hp 2-2, associated with higher 5 years mortality 
Autoimmune diseases Hp 2-2 overrepresented 
Malignancies Hp 1-1 overrepresented in breast and cervical carcinoma. 
Essential hypertension  Hp 1-1 overrepresented 
Coronary artery disease Hp 2-2 overrepresented 
Sickle cell disease Hp 1-1 associated with sickle cell disease in US blacks. 
Psychiatric disorders Hp 1-1, associated with major depression 
Hp 2-2 overrepresented in familial epilepsy, affective psychosis, and 
alcohol and drug abuse. 
present on monocytes and macrophages. Several differences have been identified between Hp 1-1, 
Hp 2-1, and Hp 2-2 with regard to these antioxidant and CD163 binding functions. Hp 1-1 protects 
low-density lipoprotein (LDL) against Hb-induced oxidation better than Hp 2-2. Hp 2-2 binds with 
a 10-fold higher affinity to CD163 compared with Hp 1-1. However, these functional differences 
between the different Hp types do not seem to be specific for the diabetic state [141]. As in other 
studies they found that the prevalence of type II diabetes mellitus is haptoglobin phenotype-
independent [142].  
Hb is a potent potential oxidant of LDL by the Fenton reaction. Hb is released from red cells with 
intravascular hemolysis and at sites of endothelial cell injury may enter into the subendothelial 
space. The amount of Hb penetrating into the blood vessel wall is increased in diabetes because of 
an increased turnover of red cells and an increase in endothelial cell dysfunction and injury [143]. 
Hp is normally found in serum in a >400 molar excess compared with free Hb, and therefore all 
intravascular free Hb will be rapidly bound by Hp, preventing Hb-induced oxidation.  In diabetes 
the antioxidant function of Hp is impaired against the glycosylated fraction of Hb (GlyHb), a 
fraction that is markedly increased in the diabetic state. Even though the GlyHb can still bind to Hp 
to form a GlyHb-Hp complex, the oxidative activity of GlyHb is not completely blocked by the 
binding of Hp. Therefore, the GlyHb-Hp complex can continue to oxidatively modify proteins such 
as LDL within the vessel wall. Hp 1-1-Hb complexes are more rapidly cleared than Hp 2-2–Hb 
complexes, which would result in significantly less oxidative damage within the vessel wall in 
diabetic individuals with Hp 1-1 compared with diabetic individuals with Hp 2-2. Several 
mechanisms may be important in understanding the mechanism whereby the protein products of 
the two different Hp alleles confer differential susceptibility to diabetics.  First, the Hp types differ 
dramatically in their shape and size and consequently in their sieving potential to enter the 
subendothelial space from the serum and bind free Hb that may be released at sites of vascular 
injury directly into the vessel wall. Second, the ability to capture the Hp-Hb complex is dependent 
on the number of cells expressing CD163 and the receptor density. It had been demonstrated that 
there is a marked decrease in the percentage of monocytes expressing membrane-associated CD163 
in individuals with diabetes. Third, the activated macrophage is a well-recognized source of 
cytokines and proteases that contributes to the atherosclerotic process [141].  
 It was found also that haptoglobin phenotype is a predictor of the risk for microvascular 
and macrovascular complications of diabetes. Specifically, diabetic patients with the 
haptoglobin 1-1 phenotype were shown to be remarkably resistant to the development of 
diabetic retinopathy, diabetic nephropathy, and cardiovascular disease.  It has been 
proposed that an increase in oxidative stress plays a crucial role in the development of 
diabetic vascular complications. Accordingly, differences in genetically endowed 
antioxidant status may confer increased or decreased susceptibility to the development of 
these diabetic vascular complications. Purified haptoglobin 1-1 is a superior antioxidant to 
purified haptoglobin 2-2 in vitro [144]. 
Diabetes is associated with an increase in the non-enzymatic glycosylation of serum proteins, 
including haptoglobin. There is severe impairment in the ability of Hp to prevent oxidation 
mediated by glycosylated hemoglobin. Diabetic patients with the haptoglobin 1-1 phenotype were 
shown to be remarkably resistant to the development of diabetic retinopathy, diabetic nephropathy, 
and cardiovascular disease. Accordingly, differences in genetically endowed antioxidant status 
may confer increased or decreased susceptibility to the development of these diabetic vascular 
complications [170, 171] 
1.11 Rationale and Objective of the Study 
 
Prevention of diabetic complications is a key issue, because of the premature morbidity 
and mortality associated with the disease.  
Understanding of risk factors for development of type 2 diabetes mellitus and its vascular 
complications can pin point at an early stage those predisposed to retinopathy, 
nephropathy, neuropathy and macrovacular diseases, so intensive treatment can be 
introduced early to eliminate the onset of complications.  
In the search for a molecular marker associated with the susceptibility to different diabetic 
complications, few studies have been carried on haptoglobin phenotypes among diabetic 
patients in Africa and no studies of this kind are available in Sudan.   Therefore the 
present study is proposed : 
 
1. To determine the pattern of type 2 diabetic complications among Sudanese 
patients. 
 
2. To determine the prevalence of haptoglobin phenotype among Type 2 Sudanese 
diabetics. 
 
3. To determine the association of diabetic complications, namely diabetic 
retinopathy, nephropathy, neuropathy and coronary heart disease with different 
haptoglobin phenotypes.    
 .  
 
 
 
 
 
 
 
 
Chapter Two 
Material and Methods 
 
2.1 Study Area and Study Group: 
This is a descriptive study, performed in Khartoum State. The study population comprised 400 
Sudanese diabetic patients. 200 were randomly selected from, Gabber-Abu Eliz diabetic health 
centre in Khartoum and the other 200 from Nour Elouen Eye hospital in Arkawit and Ahfad health 
centre in Omdurman. Ninety six patients with chronic renal failure were randomly selected from 
dialysis centers in Khartoum teaching hospital, Dr Selma Centre and From Khartoum North 
teaching hospital. This study was conducted in the period between, April 2003 and December 
2005.  
2.2 The Patients: 
Inclusion Criteria:  
The inclusion criteria for the study population were patients with type 2 diabetes mellitus, above 
forty years of age, irrespective of sex, duration of diabetes, ethnic group, occupation or residence. 
Diagnosis of type 2 diabetes was based on an absence of ketosis or need for insulin within 1 year 
of diagnosis. A hundred and six healthy controls were included. They were selected from 
Khartoum teaching hospital, Gabber-Abu Eliz Health Centre, all were above 40 years from 
different ethnic groups. They were matching for age and sex, and  free from diabetes confirmed by 
history, clinical examination and measuring the blood glucose level. 
Exclusion Criteria: 
• Type I diabetes mellitus. 
• Gestational diabetes mellitus. 
• Age below 40 years. 
• Severely ill patients. 
2.3 Data Collection & Clinical Examination 
    A brief description for the aim of the study was explained to the patients, and oral consent was 
obtained. Interview was performed using a prepared questioners which explore each patient 
characteristics, including (age, sex, tribe, residence, occupation, duration of diabetes…..etc) (see 
annex 1). 
A full clinical examination was carried out by the author, which included: 
Weight & Height:   the weight was measured with indoor clothing in kg and height in meters 
without shoes, body mass index (BMI) was calculated. BMI = kg/m2 Patients were considered as 
obese if the BMI > 30 kg/m2. 
Blood pressure:  was measured by using the standard mercury sphygmomanometer and with a 10 
×22cm cuff.  It was measured at rest in the sitting, and the standing positions. A patient was 
classified as hypertensive when the systolic blood pressure is ≥ 140 and diastolic blood pressure ≥ 
95 mmHg or more, or when the patient had previously been diagnosed as hypertensive and was on 
treatment. 
Retinopathy: was diagnosed by direct fundoscopy performed after mydriasis using 2% 
homatropics eye drops. The process was done in Khartoum Eye Hospital by the ophthalmologist 
Dr. Nada Ahmed. Patients in Nour Elouon Eye hospital were diagnosed by Dr. Babiker Haga. The 
lesions detected were categorized into cataract, non proliferative and proliferative retinopathy. 
Peripheral Neuropathy: diagnosis was based on the presence of two or more signs of the following 
findings; parathesia, absent pin prick, light touch sensation, sense of position and absent tendon 
reflexes, or muscular atrophy. The presence of postural hypotension, gestatory sweating, 
intermittent diarrhea, absent control of micturition was taken to indicate autonomic neuropathy. 
Ischemic heart disease:  diagnosis was based on the history of previous ischemic attack, taking 
medication. A standard twelve lead electrocardiogram was performed at rest to 200 patients. They 
were diagnosed by two physicians, Dr. Hisham Abdelrahim, and Dr. Salah Ahmed.  Ischemia was 
diagnosed by presence of Q wave or of left bundle branch block.  
2.4 Collection and Storage of Samples: 
Urine: Measurement of albumin excretion in a 24-h urine collection has long been the "gold 
standard" for quantitative evaluation of albuminuria in diabetic patients; however, collection errors 
due to improper timing and missed samples may lead to significant over- and underestimation of 
albuminuria. For convenience and consistency, the American Diabetes Association [145], and the 
National Kidney Foundation have recently recommended measurement of albumin-to-creatinine 
ratio (ACR) in a random spot urine collection for diagnosis of microalbuminuria. 
Microalbuminuria is diagnosed if ACR ranges between 30 and 300 µg /g creatinine [146]. A fresh 
random urine sample was taken from 200 diabetic patients for estimation of microalbuminuria and 
creatinine. The urine samples were collected in sterile containers, and centrifuged at 3000 r.p.m. 
for 3 minutes to estimate albumin. For estimation of creatinine the fresh urine was diluted 1/50 
with distilled water before using it.  
Blood:  Overnight Fasting blood samples were collected in EDTA tubes (5ml).  Supernatant was 
removed and centrifuged at 2.000 rpm for 10 minutes, kept frozen at –20 ْC for further analysis. 
For measuring, fasting blood glucose, and haptoglobin phenotype. Another 3 ml blood were taken 
and allowed to clot at room temperature and then centrifuged at 4000 r.p.m. to obtain the serum. 
The clear serum was taken immediately for analysis or stored at 2-8  ْC for 24 hours for analysis of 
cholesterol, triacylglycerol and HDL. 
 
2.5 Methods: 
Urine Examination 
 Measurement of albumin  
Principle of the method: Albumin in the urine sample causes agglutination at the latex particles 
coated with anti-human albumin The agglutination of the particles is proportional to the albumin 
concentration and can be measured by turbidimetry [147], using the Biosystem Spectrophotometer 
(Costa Brava, 30 Barcelona, Spain)  
Measurement of Creatinine    
Principle of the method:  Alkaline Picrate method, creatinine in the sample reacts with picrate in 
alkaline medium forming a colored complex, [148]. The complex formation rate is measured in a 
short period to avoid interference using Biosystem Spectrophotometer. 
 
 
 
Blood Examination 
 Measurement of glucose:   
 The principle of the method was the Glucose Oxidase/ Peroxidase [149]. Glucose in the sample 
originated, by means of the coupled reaction were, a colored complex was measured by 
spectrophotometer. 
Glucose + 1/2 O2 + H2O   → glucose oxidase   →   Gluconate + H2O2 
2 H2O2 + 4- aminoantipyrine + phenol →   peroxidase →    Quinoneimine + 4 H2O.  
 Measurement of Cholesterol:  
The principle of the method was Enzymatic Calorimetric method In the presence of cholesterol 
esterase the cholesterol esters in the sample were hydrolyzed to cholesterol and free fatty acids. 
The cholesterol produced is oxidized by cholesterol oxidase to Cholestenone and hydrogen 
peroxide. Hydrogen peroxide is detected by a Chromogenic oxygen acceptor, phenol – ampyrone, 
in the presence of peroxidase. The intensity of the red quinone formed is proportional to the 
amount of cholesterol present in the sample [150]. 
 Cholesterol esters   + H2O → Cholesterol Esterase → Cholesterol + fatty acid 
 Cholesterol    +   O2      →        Cholesterol oxidase → 4- Cholestenone + H2O2 
  2 H2O2 +   Phenol +   4 – Aminophenazone    → Peroxidase → Quinone + 4H2O 
Measurement of Triglycerides: 
The principle of the method was by Enzymatic Colorimetric method [151]. 
Triglycerides → Lipoprotein lipase → Glycerol + Fatty acids 
Glycerol + ATP → Glycerol kinase   → Glycerol -3 phosphate + ADP 
Glycerol -3 phosphate + O2 → Glycerophosphoxidase →Dihydroxyacetonephosphate + H2O2 
H2O2 + 4- AAP + 4- Chlorophenol→ Peroxidase → Quinoeimine + H2O 
 Measurement of HDL: 
Very low density lipoproteins (VLDL) and low density lipoproteins (LDL) in the sample 
precipitate with phosphotungstate and magnesium ions. The supernatant contains high density 
lipoproteins (HDL), [152]. The HDL cholesterol was measured by spectrophotometer.  
LDL was calculated by the following formula:  
LDL = total cholesterol - (TG/5 + HDL). 
 
2.5.1 Typing of human haptoglobin in Sudanese Diabetic patients and controls 
 
Discontinuous polyacrylamide gel electrophoresis (non reducing) according to Davis and 
Orenstein method [153], which was modified by Linke [154], was applied using Mini V8.10 
(BRL, Life Technologies Inc, Gaithersburg, USA) 
 
 Reagents 
• Acryl amide.  
• N, N – methylene-bis –acrylamide (Bisacrylamide). 
•  Ammonium persulphate. 
•  Tris - hydroxymethyl) amino-methane. 
• Glycine. 
• Sucrose. 
• Nitrocellulose paper. 
•  Hydrogen peroxide. 
• Tetrametheylethylenediamine. 
• Methanol and Glacial acetic acid. 
• Benzidine. 
• Tetra methylenediamine. (TEMED). 
• Bromophenol Blue. 
All above reagents were obtained from Sigma. 
 
 Preparation of the Hamolysate (Hb) 
Five milliliters of blood were collected in a heparinized tube from adult donor (O + ve), then 
centrifuged at 2000 g for 10 minutes. The sediment blood cells were washed five times in 
phosphate buffered-saline (PBS, 0.1M sodium phosphate, 0.075 M Nacl, PH 7.2). One milliliter of 
packed blood cells was lyzed for 30 minutes 3 ml-distilled water. The solution was centrifuged at 
1000 g for 30 minutes and the clear supernatant was frozen in aliquots of 1.5 ml at -70ºc and kept 
as stock solution until used. 
 
Preparation of the polyacrylamide gel solutions (stock): 
 (1) Solution A: 
This solution was prepared by dissolving 18.6 gm of Tris (hydroxymethyl amino methane) in 24 
ml of IM HCL .this solution was dissolved in a mixture of 40 ml of distilled water and 0.12 ml 
TEMED. The pH was adjusted to 8.9, and then the volume was finally completed to 74 ml with 
distilled water. 
 (2) Solution B:  
This was prepared by dissolving 3 gm of Tris- hydrochloride in 24ml of l M HCl. This solution 
was added to a mixture of 40 ml of distilled water and 0.23 ml TEMED and the pH was adjusted to 
6.7. Then the volume was completed to 74ml. 
 (3) Solution C: 
Fourteen gram of Acrylamide powder and 0.3 gm of Bis-acrylamide were dissolved in 50 ml of 
distilled water and kept in dark brown bottle until used. 
(4) Solution D: 
This was prepared by dissolving 5 gm of Acrylamde and 0.15 gm Bis Acrylamde in 50 ml of 
distilled water .This also was kept in dark brown bottle. 
(5) Solution F: 
Twenty gram of sucrose was dissolved in 50 ml distilled water. 
 (6) Solution G: 
This solution was freshly prepared by dissolving 0.005 gm ammonium persulfate in 100 µl of 
distilled water (for resolving gel), or 0.015 gm of ammonium persulfate in 100 µl of distilled water 
(for stacking gel). 
 (7) Solution H (Electrophoresis buffer): 
This was prepared by dissolving 6 gm of Tris-base and 28.8 gm glycine in 800 ml distilled water 
and then the pH was adjusted to 8.3 before completing the volume to 1 liter. 
(8) Loading buffer: 
Prepared by adding a few crystals of bromophenol powder to solution F. 
 
Casting the gel: 
Two clean plates (8×10cm) and (7×10cm) respectively were placed on the bench and two spacers 
(0.75mm thick) were put along the shorter edges of the first plate. 
The second small plate was placed on the top of the spacers, adjusted to the lower edge of the first 
plate, and carefully leveled. After that the two plates were clamped tightly with the spacers in 
between. Then the lower edge of the sandwich glass was then immersed in a warm solution of 1% 
(w/v) agarose in distilled water and was left to dry to seal the bottom of the sandwich. 
 
 Preparation of the polyacrylamide gels (non-reducing): 
(1) 4.7 % poly acrylamide resolving (separating) gel: 
Three and half milliliter of solution A was mixed with 3.5ml of solution C, 4ml distilled water, 10 
µl TEMED and finally 100 µl of solution G (10 % ammonium persulfate) freshly prepared.  Then 
immediately the prepared mixture (resolving gel) was slowly casted from one edge filling 4/5 of 
the sandwich glass after that applying 1ml of methanol carefully leveled the surface of the gel. 
Then the gel left for 45-60 Minutes to polymerize. After complete polymerization of the gel, the 
methanol was poured out by mean of tissue paper. 
(2)  2. 5% polyacrylamide stacking gel: 
This gel was prepared by mixing 1ml of solution B,  2 ml of solution D, 1 ml of solution F, 18 µl 
TEMED and finally, 100 µl freshly prepared solution G (15% ammonium persulfate ). Then the 
mixture was carefully poured on one edge of the assembly over the polymerized resolving gel to 
almost completely filling the remaining part of the sandwich. Immediately after that, a ten-toothed 
comb was inserted into the gel and left for about 30 minutes to form the sample wells.  After that, 
the comb was carefully removed and the wells were filled with electrophoresis buffer to prevent 
drying. 
(3) Preparation of loading sample mixture and separation of the samples: 
Seven micro-liters of serum or plasma samples were added to a mixture of 4µl of the Haemolysate 
(Hb) and 5µl of the loading Buffer. Then 7µl from each prepared mixture was added to each well. 
The loaded gels were then placed in the electrophoresis tank, which was filled with the 
electrophoresis buffer.  
(4) Running the gel and separating the proteins. 
The mini-gel tank was filled to two thirds with electrophoresis buffer. The glass plate assemblies 
were placed in the buffer with the large glass towards the wall of the tank and the smaller glass 
plate towards the inner part of the tank. Then the gel wedge block was situated between. The 
buffer level was adjusted to immerse the electrodes. The tank cover was then placed in its right 
position and the electrodes connected to a power supply unit. Then a voltage of 85-100 V was 
applied and the run was continued till the dye front reach the resolving gel level. The voltage was 
then elevated to 150 V and the run was continued until the blue line passed out of the gel. Very 
faint yellow bands remain on the gel and the run continued until it reached 1 cm from the bottom 
of the gel. Then the electrodes were disconnected, the cover of the tank was removed, the two 
glasses were separated smoothly from each other and the gels were covered with the 
electrophoresis buffer to prevent drying. The gels were carefully handled and kept in benzidine 
stain  (described below) for 15-30 minutes, till the bands appear and then the stain replaced with 
distilled water and then photographed.  
(5) Benzidine Stain 
The stain was prepared by dissolving 0.2 gm of Benzidine powder in 40 ml of distilled water and 
heated for few minutes. Then a mixture of 15 ml glacial acetic acid was added with continues 
heating till we get a clear solution. Finally, 60 µl of hydrogen peroxide (H2O2) was added.  
(6)  Typing of haptoglobin 
Different structural features have been used in the typing of Hp phenotype. Those features were 
described in Figure 2:  
1. Hp 1-1 phenotype appears as only one thick fast immigrating band closer to the free 
hemoglobin. 
2. Hp 2-1 phenotype appears as multiple fine, slow moving bands and has the same 
thickness in addition to a band corresponding to the Hp 1-1 band. 
3.  Hp 2-2 phenotype shows also a series of multiple bands, which are fine and close to 
each other. However, the fastest migrating band appears fainter than its preceding band. 
 
Fig 1.5-1.16: Photographs of different haptoglobin phenotypes:  
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2.6 Data Analysis 
 
The statistical analysis was performed with a personal computer using the statistical package for 
social science (SPSS). Descriptive statistics presented in the tables were based on the observed 
data. The results of biometric and biochemical variables were expressed as mean (mean ± SE). The 
differences between the groups were assessed by means of Z test and the Independent Sample t - 
test. The Odds Ratio (OR) with 95% Confidence interval (95% CI) was calculated from 2× 2 tables 
and chi –square, or Fisher's exact test. Pearson correlation coefficients (r), based on the original 
observations, were utilized to study the relationship between different biometric and biochemical 
variables. Significance was taken as P< 0.05. 
Charts were done using the Excel software 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Three 
 
Results 
 
           Four hundred diabetic patients were included in our study, with a male to female ratio 1: 
1.7.  The mean age of the patients in years was 54.3 ± 9.3, and the mean age of diabetic onset was 
45.3 ± 9.5. Duration of diabetes range from 1-35 years with a mean value of 10.3 years ± 7.2.  The 
majority of the patients were from northern Sudan 74.3 %, while 14.3 from central origin, 12 % 
from eastern origin, 3.0 % from western origin and 0.5 % from southern origin. Family history of 
diabetes in first degree relatives was obtained in 56.5 % (n= 226). 192 of the patients were 
overweight comprising (48 %) of patients, Only 10 patients were undernourished (BMI < 19 kgm2) 
(Table 3.1) 
Two hundred and fifty seven (73 %) patients were taking glibenclamide, 52 patients (20.2 %) were 
on metformin and 15 were on a combination of metformin and glibeclamide. 35 patients (8.8 %) 
were on insulin and 61 (15.3 %) were on combination of insulin and oral hypoglycemic drugs. 47 
patients (7.7%) were on diet alone.  From our group 61 diabetics (15.3%) had history of 
hospitalization, 7.1% was from diabetic ketoacidosis, and other from other different diabetic 
complications 
Patients were classified according to presence or absence of diabetic complications (Fig 3.1).  
Hundred and fifty eight patients (40 %) showed no apparent complication while in 242 (60 %) one 
or more diabetic complications were found. In eighty three patients (20.8 %) more than one 
complication was detected. Eye complications were predicted in 188, cataract in 74 (18.5 %), non - 
proliferative diabetic retinopathy in 87 (21.7 %), and proliferative retinopathy in 27 (6.7 %). Sixty 
six (33 %) had diabetic nephropathy, and 67 (16.8 %) had diabetic neuropathy, and patients with 
coronary heart disease were, 47 (11.8 %) (Fig 3.2). 
The mean age of the complicated patients was 58.2 years ± 0.56 which was significantly more than 
the uncomplicated patients  51.1 ± 0.58 (p= 0.000). It was found that more than half of the patients 
in the complicated group were illiterate n= 133 (55 %), the difference was not highly statistically 
significant p=0.058. Prolonged duration of diabetes was more profound in the complicated group 
as the mean ± SE duration in years was 12.7 ± 0.551, compared to 6.4 ± 0.490 in uncomplicated 
group p= 0.000. 
No significant difference was found between the two groups regarding sex, age of onset of 
diabetes, ethnicity, smoking, first degree family history and regular medical follow up in diabetic 
health centers or in private clinics. (Table 3.2) 
Clinical data of the complicated and the uncomplicated diabetics were described in (Table 3.3).  
Both groups were found to be overweight, as the mean body mass index was > 25 kg/m2 for the 
complicated and uncomplicated group (p= 0.283). A highly significant difference (p <0.000) was 
found among both groups regarding different medication used. 20.7 % of the patients on mixed 
therapy (insulin + oral hypoglycemic) developed complication compared to 7 % in the other group. 
In our group 104 (26%) diabetics were found to be hypertensive. Among the hypertensive 72 
patients (69 %) had one or more diabetic complications (p=0.035). The biochemical variables and 
their correlation to complicated and uncomplicated diabetic were shown in (Table 3.4).  The mean 
fasting blood glucose was significantly higher 12.1 mmol/L ± 0.320 among the complicated 
groups, compared to the uncomplicated group which was 11.3 ± 0.48 (p = 0.021). The mean serum 
for cholesterol and triacylglycerol were higher among the complicated group, but the difference 
was not significant.  The mean serum HDL/cholesterol was significantly lower among the 
complicated 83.3 mg/dl ± 3.42 group compared to uncomplicated group 95.9 ± 2.52 (p= 0.021).  
The LDL/ cholesterol (mean mg/dl ± SE) level was found to be higher among the complicated 
group 169.9 ± 5.84 compared to the uncomplicated group 147.8 ± 3.51 (p= 0.001). The 
haptoglobin phenotype distribution showed no significant difference among complicated and 
uncomplicated groups.  The haptoglobin phenotype 1-1 among the complicated patients was found 
in 21.5 % (n= 52), while Hp 2-1 in 52.9 % (n= 128), and Hp 2-2 in 25.6 % (n= 62). In the 
complicated diabetics, Hp 1-1 was found in 19 % (n= 30), Hp 2-1 in 48.7 % (n= 77) and Hp 2-2 in 
32.3 % (n= 51), p = 0.347.  
(Table 3.5), describes the general characteristics of patients with different diabetic complications. 
The mean age ± SE of diabetic onset was only significantly higher among patients with coronary 
heart disease 49.6 ± 1.44 (p= 0.001). The development of diabetic complication was significantly 
correlated with ageing among patients with diabetic neuropathy, eye complications and  coronary 
heart disease as their mean age /years ± SE was 60.4 ± 0.974,  59.3 ± 0.622, and 58.5 ± 1.305, 
respectively. Duration of diabetes was found to be significantly correlated to diabetic neuropathy, 
and different eye complications. It was 15.7 years ± 0.569 in diabetic neuropathy, 14 years ± 0.615 
in eye complications, 8.8 ± 1.048 in coronary heart disease and 7.76 in diabetic nephropathy. 
Illiteracy was found to be correlated only to the prevalence of different eye complications and 
diabetic neuropathy. 
Smoking, first degree family history and regular medical follow up were significantly correlated 
only to diabetic neuropathy, as the p value was <0.05. 
Sex and ethnicity had no correlation with different diabetic complications. 
The clinical characteristics of the different diabetic complications were shown in (Table 3.6).   
Most of the patients were overweight as the mean body mass index for the different complications 
was more than 25 kg/m2. Hypertension was found to be more apparent in coronary heart disease 
patients (31.9 %), but we found that neither body mass index nor hypertension had significant 
correlation with the different diabetic complications.  Medication used by patients was 
significantly correlated to different eye complications and to diabetic neuropathy. As a high 
percentage of them was on mixed therapeutic regimen (insulin & oral hypoglycemic drugs).  
Biochemical variables were tested among various diabetic complications (Table 3.7).  Eye 
complications were strongly correlated to the mean fasting blood glucose 11.0 mmol/ dl ± 0.244 
(p= 0.003), mean serum cholesterol 203.4 mg/dl ±5.99 (p= 0.001), mean HDL/cholesterol   83.2 
mg/dl ± 3.76 (p= 0.008), and the mean LDL /cholesterol 168 mg/dl ± 6.80 (0.000).  Regarding the 
other diabetic complications no significant correlation was found with any of the biochemical 
variables.  Hp 2-1 was overrepresented in the different diabetic complications, but no significant 
correlation was found.  
Table 3.8 shows the prevalence of different diabetic complications among controlled and 
uncontrolled patients. There was no significant difference in the prevalence of nephropathy, 
neuropathy and coronary heart disease between the two groups, but the prevalence of cataract and 
retinopathy was significantly higher in the poorly controlled group (p<0.001) .  The complications 
of diabetes in relation to the duration of diabetes mellitus were shown in (Table 3.9).  The 
incidence of these complications was found to increase with longer duration of the disease. It was 
significantly higher in patients who had diabetes for more than 10 years, than those with diabetes < 
5 years (p<0.001). 
The main risk factors associated with diabetic complications were shown in (Table 3.10).   
Diabetic retinopathy and neuropathy share some of the associated risk factors, as prolonged 
duration of diabetes, old age, and insulin therapy (p<0.001).   Illiteracy was associated with 
diabetic retinopathy only (p< 0.01) 
Smoking found to be a risk factor for coronary heart disease p < 0.05.  
Different diabetic complications were found to be risk factors or markers for each other, and this 
was apparent in (Table 3.10). Diabetic nephropathy had a strong association with all complications 
with a p value < 0.001. Coronary heart disease had only weak association with diabetic 
nephropathy p< 0.05. 
Hyperglycemia, high LDL/ cholesterol, and low HDL/ cholesterol level were found to be a strong 
biochemical associated risk factors for development of diabetic retinopathy. Serum cholesterol 
represents a weak associated risk factor for diabetic nephropathy as shows in (Table 3.11). 
In this study, the haptoglobin phenotypes of the 400 diabetic patients and 106 healthy controls 
were determined. Hp 1-1 was found in 17 % (n=18) of the controls and in 20.5% (N= 82) of the 
diabetic patients. Hp phenotype 2-1 was higher in the control group as it represent 58.5% (n= 62) 
while in the diabetic patients it was found in 51.3% (n=205). Hp 2-2 was higher among the 
diabetic patients 28.3 % (n= 113) while in the controls it was found in 24.5% (n=26). (Fig 3.3) 
In conclusion haptoglobin 2-1 was the main Hp phenotype found among patients and controls. The 
difference between the two groups was not significant   P = 0.411. 
The distribution of the different tribes among the five regions (Table 3.12) shows the haptoglobin 
distribution among the 400 diabetic patients and 106 healthy controls.  None of the control group 
had Hp 1-1 in the central, southern, and eastern regions, while in the western region it represent 28 
% and in the northern region  only 16.4 %.  Hp 2-1 was nearly equally distributed among the 
patients in the northern (45.6 %), central (54.5 %) and, southern (50 %), eastern (50 %), and the 
least among the western (31.3 %).  Hp 2-2 was 0 % among the southern group, in the central 
region was 31.5 % among the patients and (38.7 %) among the controls, while in the northern the 
patients are more (26.6 %) and the controls (20.8 %). In the eastern and western region the control 
represent (55.5 %) and 44 % respectively. In conclusion the majority of the patients had Hp 2-1, 
and 2-2, except the western, where the different Hp phenotypes where nearly equally distributed. 
There was a significant difference in the distribution of Hp phenotype among the different tribes in 
Sudan. P= 0.028. 
Among the 400 diabetic patients 26% (n=104) were hypertensive. The haptoglobin phenotype 1-1 
distribution among the hypertensive group was 23.1 % (n=24), while within the non- hypertensive 
it represent 19.6% (n=24). Hp 2-2 was higher among non-hypertensive 30.7% (n=91) while in 
hypertensive it was 21.2 % (n=22), (Fig  3.4). 
The difference between the groups was not significant, P= 0.172. 
No significant association was found between Haptoglobin phenotype obesity and sex as the p 
value was >0.05.  
The distribution of haptoglobin phenotypes 1-1, 2-1, and 2-2 among the different causes of chronic 
renal failure was shown in (Table 3.13).    Haptoglobin 2-1 comprise the highest percentage among 
patients classified as unknown, 57.9 % (n =22), while Hp 1-1 and Hp 2-2 were equally distributed 
among the two groups, 21% for each.  Among diabetic patients the majority were Hp 2-1, 56% 
(n=14), followed by Hp1-1 found in 7 patients (28 %), while Hp2-2 was found only in 4 patients 
(16 %).  In chronic glomerulonephritis there was an equal distribution between Hp 1-1 and Hp 2-2 
among the patients as it represent 30 % (n=6) for each.  In hypertensive patients Hp 2-1 was the 
main phenotype distributed among the group, which represent (57.1%). In contrast to patients with 
renal obstruction n Hp 1-1 was found in the majority of cases (66.7 %). There was no significant 
difference in the distribution of haptoglobin within the different groups the p value was 0.250.  
 
 
 
 
 
 
 
Table 3.1:  Personal characteristics of type 2 diabetic patient on study 
 
 
 
 
 
 
 
 
 
 
Variable 
 
 
No. of  patients  = 400 
Sex  M/F    % 170/ 230         ( 42.5/ 57.5) 
Age of onset /years  
Mean   ± SE 45  ± 9.5 
Age  / years 
Mean   ± SE 
 
55  ± 8.8 
Education 
Illiterate/ Primary/University 
 
203/ 142/ 55     (50.8/ 35.5/ 13.8 %) 
Ethnic Groups               % 
North/central/west/east/south 
 
297/ 57/ 32/ 12/2  (74/14.3/8/3/0.5%) 
Patients on regular medical follow up 281    (70.3%) 
Duration of DM years 
Mean   ± SE 
10.1   ± 0.35 
Positive family history 
 
226      (56.5%) 
Smoker 21     (5.3 %) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.1: Frequency of complicated and uncomplicated diabetics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ig 3.2: Distribution of different complications among the diabetic patients. 
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Table 3.2: Characteristics of patients with complicated and uncomplicated diabetes mellitus 
 
 
 
 
 
 
 
28%
18.5%
33%
16.8%
11.8%
Diabetic Retinopathy
Cataract
Diabetic Nephropathy
Diabetic Neuropathy
Coronary heart disease
 
 
 
  Variable 
Complicated  diabetics  
N =242   (60%)                
Uncomplicated diabetics 
N = 158 (40 %) 
 
P value 
Sex  M/F        43 / 57 %  42 / 48   %         0.975 
Age of onset /years 
Mean   ± SE 
 
  45.5  ± 0.66 
 
45  ± 0.66 
 
0.660 
Age  / years 
Mean   ± SE 
 
58.2  ± 0.56 
 
 51.1  ± 0.58 
 
0.000* 
Education                    
Illiterate/ Primary/University                      
 
55/ 31/ 14  % 
 
  44 / 42 / 13 % 
 
0.058 
Ethnic Groups               % 
North/central/west/east/south                      
 
 75 / 14 / 8/ 3 / 0 
 
 73/  15/  8/ 3 /1 
 
0.497 
Patients on regular follow up                      67.7 % 
 
71.9 % 0.371 
Duration of DM years 
Mean   ± SE 
12.7  ± 0.551  6.4  ± 0.490 0.000* 
Positive family history     
                              
58.3 %  53.8 %                 0.378 
Smoker                          5.8 %   4.4 % 0.553 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3:  Clinical data of patients with complicated and uncomplicated diabetes mellitus. 
 
 
 
 
 
 
 
Variable Complicated    diabetics Uncomplicated  diabetics P   value 
N =242   (60%)                N = 158 (40 %) 
BMI       Mean   ± SE  27   ± 0.29 28    ± 0.41 0.283 
Medication:  Diet / oral 
hypoglycemic drugs /insulin/ 
Mixed  ( oral HD + Insulin)                 
 
7.4 / 62.4 / 9.5/ 20.7 % 
 
18.4 / 67 /15/ 7 % 
 
0.000** 
Hypertension  
N= 104                                                 
 
72                      69 % 
 
32          30.8% 
 
0.034* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4:  Biochemical variables of patients with complicated and uncomplicated diabetes 
mellitus. 
 
 
 
 
 
 
 
 
Variable Complicated Uncomplicated  P    value 
diabetics  
N =242   (60%)      
diabetics 
N = 158 (40 %) 
Fasting blood Glucose 
(mean mmol/L ± SE) 
 
12.1  ± 0.320 
 
11.3  ± 0.48 
 
0.021* 
Serum cholesterol 
(mean mg/dl ± SE) 
 
206   ± 4.526 
 
203    ± 3.882 
 
0.677 
Serum triacylglycerol 
(mean mg/dl ± SE) 
 
165   ± 5.12 
 
154     ± 5.62 
 
0.182 
HDL / cholesterol 
(mean mg/dl ± SE) 
 
83.3   ± 3.48 
 
95.9   ± 2.52 
 
0.021* 
LDL/ cholesterol 
(mean mg/dl ± SE) 
 
169.9   ± 5.84  
 
147.8    ± 3.51 
 
0.001* 
Hp phenotype     % 
1-1 / 2-1 / 2-2 
 
21.5 /52.9 / 25.6 
 
19 / 48.7 / 32.3 
 
        0.347 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5:  Characteristics of patients with different diabetic complications. 
 
 
 
 
 
 
 Variables 
 
Eye Complications 
N= 188  
 
D. Nephropathy 
N= 66 
 
D.  Neuropathy 
N= 67 
 
Coronary  H disease 
N= 47 
 
Sex   M/F        % 44 / 55.9   
  P= 0.396 
39.4 / 60.6  
P= 936 
46.3 /  53.7 
P= 0.494 
42.6 / 57.4 
P=  0.994 
Age of onset /years 
Mean   ± SE 
45  ± 0.75 
p= 0.541 
46 ± 1.19 
p= 0.116 
44.5 ± 1.31 
p= 0.471  
49.6 ± 1.44 
p= 0.001* 
Age  / years 
Mean   ± SE 
59.3  ± 0.622 
p=0.000* 
 54.1 ± 1.12 
p= 0.787 
60.4 ± 0.974 
p= 0.000* 
58.5 ± 1.305 
p= 0.012* 
Education   % 
Illiterate/ Primary/University       
55.3/ 29.8 / 14.9 
P= 0.002* 
53/ 33.3/13.6 
P= 0.636   
62.7/ 25.4/12 
P= 0.092* 
63.8/29.8/6.4 
P= 0.112 
Ethnic Groups   % 
North/central/west/east/south       
76.6/12.8/ /8.5/2/0 
P= 0.463 
74/16.7/1.5/3/4.5 
P= 0.887 
77.6/7.5/13.4/1.5/0 
P= 0.152 
70.2/21.3/2/6.4/0 
P= 0.161 
Patients on regular follow up       
% 
70.2 
P= 0.988 
75.8 
P= 0.349 
80.6 
P= 0.042* 
78.7 
P=0.176 
Duration of DM years 
Mean   ± SE 
14  ± 0.615 
p= 0.000* 
 7.76  ± 0.822 
p= 0.212 
15.7 ± 0.569 
 p= 0.000* 
8.8 ± 1.048 
p= 0.195 
Positive family history    %     55.3  
P= 0.612 
37.4 
P= 0.152  
71.6 
P=0.006* 
51.1 
P= 0.424 
Smoker        %    5.9 
P= 0.612 
  4.5 
P= 0.836 
10.4 
P= 0.037* 
4.3 
0.745 
 
 
 
 
 
 
 
 
 
 
 
Table 3.6:   Clinical data of patients with complicated and uncomplicated diabetes mellitus. 
 
 
 
 
 
 
 
 
     
       Variable Diabetic Retinopathy 
N= 188  
D. Nephropathy 
N= 66 
D.  Neuropathy 
N= 67 
Coronary heart disease 
N= 47 
 
BMI       Mean   ± SE 
  
27.5  ± 0.32 
p= 0.627 
 
27.9 ± 0.569 
p= 0.865 
 
27.5 ± 0.512 
 p= 0.735 
 
27.4    ± 0.696 
p= 0.732 
 
Hypertension           
N           %     
 
53                    28.2 % 
P= 0.341 
 
17                   25.8 % 
P= 0.515 
  
20                29.9 % 
P= 0.447 
 
15         31.9 % 
P= 0.376 
 
Medication:  %       Diet / oral 
hypoglycemic drugs /insulin /      
Mixed  ( oral HD + Insulin)         
 
5.3 /62.8 / 45.7/23.4  
P= 0.000* 
 
10.6/ 66.7/ 9.1/13.6 
P= 0.151 
 
3/  55.2/11.9/29.9 
P=0.000* 
 
14.9/ 57.4/17/10.6 
P= 0.125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.7: Biochemical variables associated with different diabetic complications. 
 
 
 
 
 
 
 
 
 
 
           Variable 
 
Diabetic Retinopathy 
 
D. Nephropathy 
 
D.  Neuropathy 
 
C. Heart D 
N= 188  N= 66 N= 67 N= 47 
 
Fasting blood Glucose 
(mean mmol/L ± SE) 
11.0 ± 0.244 
P= 0.003* 
12.2 ± 0.483 
P= 0.670 
11.6 ±0.207 
P=0.924 
11.5 ± 0.445 
P= 0.798 
Serum cholesterol 
(mean mg/dl ± SE) 
203.4 ± 5.99 
P= 0.001* 
 205 ± 5.804 
P= 0.612 
205  ± 5.56 
P= 0.778 
207 ±8.91 
P= 0.728 
Serum triacylglycerol 
(mean mg/dl ± SE) 
163 ± 5.99 
P=0.395 
155.6 ± 8.65 
P= 0.612 
168 ± 10.7 
P= 0.341 
170 ± 10.0 
P= 0.337 
HDL / cholesterol 
(mean mg/dl ± SE) 
83.2 ± 3.76 
P=0.008* 
92± 4.82 
P= 0.612 
 86 ±  5.03 
P= 0.291 
84  ± 8.8 
P= 0.929 
LDL/ cholesterol 
(mean mg/dl ± SE) 
168 ± 6.8 
P= 0.00* 
163 ± 5.23 
P= 0.312 
166 ± 6.3 
P= 0.694 
 183 ± 4.71 
P= 0.091* 
Hp phenotype            
1-1 / 2-1 / 2-2    % 
21.8 /53.7/ 24.5 
P= 0.361 
19.7 / 51.5/ 28.8 
P= 0.979 
22.4/ 50.7 / 26.9 
P= 0.906 
23.4 / 51.1/11.8 
P= 0.838 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. 8: Prevalence of diabetic complications in relation to metabolic  
Control 
 
 
 
 
 
  
*P < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.9:  Type 2 diabetes mellitus complications in relation to the duration of diabetes. 
 
 
 
Mean fasting blood  
glucose 
 
Cataract 
 
D.Retinopathy 
 
D.Nephropathy 
. 
D.Neuropathy  
 
CHD 
 
< 8 mmol/L 
Controlled   N= 86 
 
20   (23.2%) 
 
 25    (29 %) 
 
13        (31 %) 
 
13    (15%) 
 
9    (10.4%) 
 
> 8 mmol/L 
Uncontrolled  N= 314 
 
 
54    (17 %)* 
 
89    (28.3%)* 
 
53       (33.5%) 
 
54    (17.2%) 
 
38     (12%) 
 
Complication 
 
< 5 years 
N=202 
 
5-10 years 
N=149 
 
11-15 years 
N=109 
 
>15 years 
N=201 
 
Total 
N=660 
 
Overweight &Obesity 
    
108 
(74 %) 
   
72 
(80 %) 
    
 40 
(66.7 %) 
   
 72 
(69.2) 
 
 292 
(73%) 
         
 * P< 0.001 
significant difference from patients with diabetes < 5 years.  
 
 
 
 
 
 
 
 
Table 3.10: Risk factors associated with diabetic complications expressed as odds ratio (OR). 
 
 
 
   
 Variable 
 
Diabetic Retinopathy 
N= 188           
OR ( 95 %CI) 
 
D. Nephropathy 
N= 66 
OR ( 95 %CI) 
 
D.  Neuropathy 
N= 67 
OR ( 95 %CI) 
 
Coronary heart disease 
N= 47 
OR ( 95 %CI) 
 
Age > 60 years  Mean   ± SE 
N= 153    (38.3 %) 
 
     59      (38.6 %) ** 
 5.010 (3.23-7.76) 
 
19     (32.2 %) 
0.95 (0.497-1.817) 
 
40    (26.1%) **  
2.884 (1.684-4.941) 
 
     22                (14.4 %) 
1.491 (0.808 – 2.751) 
Duration > 20 years     89        (47.8 %) **      21         (41.2 %)       52        (28 %) **  19                (10.2 %) 
 
Cataract 
     
22 
(15.1 %) 
    
 15 
(16.7 %) 
     
 9 
(15 %) 
    
28* 
(26.9 %) 
 
  74 
(18.5%) 
 
D. Retinopathy 
 
   16 
(11 %) 
 
    17 
(18.9%) 
 
    26 
(43.3) 
 
   55 * 
(52.9 %) 
 
  114 
(28.5%) 
 
D. nephropathy 
 
    28 
(27.5 %) 
 
   21 
(38.9 %) 
 
    8 
(42.9 %) 
 
    9 
(36 %) 
 
   66 
(33 %) 
 
D. Neuropathy 
 
     8 
(5.5 %) 
 
   11 
(12.2 %) 
 
    19 
(31.7 %) 
 
   29* 
(27.9%) 
 
   67 
(16.8 %) 
 
CHD 
 
    20 
(13.7 %) 
 
    13 
(14.4 %) 
 
     6 
(10.0 %) 
 
    8 
(7.7 %) 
 
 
  47 
(11.8 %) 
  N= 186   (46.5 %) 5.946 ( 3.858- 9.158) 1.612 ( 0.838-3.125) 5.148 (2.784-9.41)  0.764 (9.412-1.419) 
Illiteracy  
N=203 (50.8%) 
  52        (25.6 %) ** 
4.012 ( 2.34-6.57) 
      35         (30.4%) 
1.312 (.724-2.377) 
       41        (20.2 %) 
0.601 (0.351-1.217) 
        30              (14.8 %) 
0.545 (.290-1.023) 
BMI > 30 
N= 292 (73 %) 
       84       (28.8 %) 
0.766 (.492-1.192) 
       50        (32.3 %) 
0.863 ( .430-1.733) 
        51          (17.5%) 
1.217 (.616-2.241) 
   34              (11.6 %) 
0.963 (.489-1.903) 
Smoking 
N=21 (5.3 %) 
     3          (2.6 %0 
1.255 (.521-3.026) 
    3           (4.5 %) 
0.846  (.216-3.454) 
     7         (10.4 %)* 
2.658  (1.030-6.862) 
        2               (4.3 %) 
0.781 (.176-3.466) 
Insulin therapy 
N= 97 (24 %) 
   40         (41.2 %) ** 
2.348 (1.466-3.761) 
      15        (22.7 %) 
1.419 (.684-2.946) 
    28        (28.9 %) ** 
2.747 (1.58-4.776) 
       13            (13.4 %) 
1.224 (.618-2.428) 
Hypertension 
104 (26%) 
        35          (30.8 %) 
1.239 (.792-1.939) 
        17        (25.8 %) 
1.256 (.631-2.502) 
      20          (29.9 %) 
1.261 (.707-2.250) 
        15              (14.4 %) 
     1.390 (.720-2.687) 
Diabetic retinopathy 
N= 188           
……………….          33 (50.8 %) ** 
3.188 (1.766-5.955) 
        54 (28.7%) ** 
6.169 (3.240-11.76) 
           21 (11.2 %) 
0.900 ( .488-1.659) 
D. Nephropathy 
N= 66 
       25 (37.9%) ** 
3.188 ( 1.76 – 5.955) 
……………….          12 (18.2 %)* 
2.71  (1.123-6.765) 
17 (25.8%)* 
2.236 (1.064-4.697) 
D.  Neuropathy 
N= 67 
      33 (49.3%) ** 
6.169 (3.246-11.745) 
      12 (54.5 %)* 
2.756 (1.123-6.764) 
…………………            8 (11.9 %) 
1.022 (.455- 2.299) 
Coronary heart disease 
N= 47 
          9 (21.3 %) 
0.900 (.488-1.659) 
     17 (48.6%)* 
2.236 (1.064-4.697) 
8 (17 %) 
1.002 ( .455- 2.256) 
……………………. 
 
  *P < 0.05. 
  **P <0.001 
 
 
 
Table 3.11: Biochemical risk factors associated with diabetic complications expressed as 
Odds Ratio (OR). 
 
 
 
 
 
       Variable 
 
Diabetic Retinopathy 
N= 188           
OR ( 95 %CI) 
 
D. Nephropathy 
N= 66 
OR ( 95 %CI) 
 
D.  Neuropathy 
N= 67 
OR ( 95 %CI) 
 
Coronary heart disease 
N= 47 
OR ( 95 %CI) 
 
                           
Fasting blood glucose 
 > 10 mmol/L         
N = 219     (54.8%) 
     53   (28.2 %) ** 
0.567 (.381 - .841) 
 
     39    (33%) 
1.136 (.625 – 2.065) 
       40     (16 %) 
1.275 (.748 -2.173) 
26    (11.8%) 
1.026 (.557 -1.893) 
Serum Cholesterol > 250 
mg/dl        N= 74      (18.5 %) 
        18     (28.5 %) 
0.888 ( .535 – 1.475) 
        5    (33 %)* 
0.357 (0.130 - 0.981) 
       13    (16.8 %) 
1.073 (.551 -2.080) 
 8     (11.8 %) 
0.892 ( .392 – 1.988)  
Serum Triacylglycerol > 160 
mg/dl      N= 162      (40.5 %) 
         44    (27.2 %) 
1.036 ( .695 – 1.546) 
       25    (30.9 %) 
0.849 ( .464 – 1.554) 
         29    (17.9 %) 
1.148 ( .675 – 1.951) 
23 (14.2 %) 
1.475 (.801 – 2.717) 
HDL/cholesterol < 90mg/dl 
N= 118 (59 %) 
         46    (56.1 %) ** 
2.39 ( 2.34 – 4.67) 
        32      (39 %) 
1.581 ( .871 – 2.870) 
18   (22 %) 
0.948 ( .482 – 1.865) 
          5      (6.1 %) 
1.030 ( .315 – 3.364) 
LDL/ cholesterol > 190 
mg/dl            N= 64 (32 %) 
      34     (53.1 %) ** 
0.235 ( .356 - .216) 
         21     (32.8 %) 
0.988 ( .525 – 1.859) 
      13    (20.3 %) 
 0.828 ( .401-1.713) 
        5     (7.8 %) 
1.562 ( .476 – 5.125) 
Hp Homozygote phenotype 
 2-1/ 2-2      N= 318 (79.5 %) 
         87   (27.4 %) 
.860 ( .529 – 1.397) 
          53    (33.1 %) 
1.029 ( .491 – 2.154) 
       52   (16.4 %) 
.873 ( .463 – 1.646) 
         36    (11.3 %) 
0.824 ( .400 – 1.699) 
 
   * p <0.05 
** p <0. 001 
 
 
 
 
 
 
 
 
 
Figure 3.3    Haptoglobin phenotype in plasma of Sudanese diabetic patients and controls. 
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Table 3.12:  Distribution of Haptoglobin phenotype among diabetic patients and controls in 
different regions of Sudan. 
 
 
 
 
 
 
 Hp.phenotype 
 
Central S.  
N             % 
 
Northern S. 
N             % 
 
Southern. S 
N             % 
 
Eastern S. 
N            %      
 
Western S. 
N                 % 
1-1 Patients 
Control 
     
13          22.8 
0.0          0.0 
56          18.9 
11         16.4 
1            50 
0.0          0.0 
1             8.3 
0.0          0.0 
11               34.4 
7                28.0      
Total 13 67 1 1 18 
2-1 Patients 
       Control 
           
26          45.6 
8            61.3 
162       54.5 
42         62.6 
1             50 
1            100 
6             50 
4           44.4 
10               31.3 
7                  28 
Total 34 204 2 10 17 
2-2 patients 
          Control 
 
18          31.5 
5            38.7 
79         26.6 
14         20.8 
0.0          0.0 
0.0          0.0 
5           41.7 
5          55.6 
5                 31.3 
11               44 
Total 23 93       0 10 16 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.4:  Distribution of Haptoglobin phenotype 
 among hypertensive patients. 
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 Table 3.13: Distribution of haptoglobin phenotype within different causes of chronic renal 
failure. 
 
 
 
 
 
 
     
               Variable Hp phenotype  1-1 
N= 27 
Hp phenotype   2-1 
N= 49 
Hp phenotype 2-2     
N= 20 
 
Diabetes mellitus            N= 25    
 
     7                 25.9 % 
 
      14            28.6 % 
 
        4             20 % 
 
Chronic glomerulo- nephritis. 
N= 20                 
 
    6                  22.2 % 
 
      8               16.3 % 
 
      6               30 % 
 
Hypertension                     N= 7 
 
     2                   7.4 %   
 
      4                 8.2 %           
 
      1               5 % 
 
Obstructive renal lesions   N= 6 
 
     4                 14.8 % 
 
      1                    2 % 
 
      1                5 % 
 
Unknown cause              N = 38 
 
     8                 29.6 % 
       
      22             44.9 % 
 
     8                40 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                  Chapter Four 
Discussion 
The present study showed that the highest prevalence of diabetes (35%) was found in the age 
group 40-50 years, this age was lower than that observed in European countries [155].  This might 
be related to less longevity in our society, as it has been shown that the incidence of type 2 
diabetes increase with age [99]. In our study we found that most of the patients were from the 
northern and the central region with an Arab descent. This high prevalence reflects a function of 
the degree of genetic admixture in the offspring of hybrid populations [156].  On the other hand 
environmental factors, such as reduced physical activity, increased obesity and increased energy 
intake, may be important for this high prevalence of diabetes. 
Diabetes was commoner in females with a ratio of 1.7:1 which is in accordance with other 
observations. [99,157].  A positive first degree family history of diabetes was found in 56.5%, this 
may probably reflects the likelihood of genetic predisposition to diabetes in our country [158] The 
frequency of family history was higher among over weight and obese subjects (76.1%) compared 
to normal BMI subjects (23 .9 %). 
Overweight and obesity was found in 48% of our patients it was much higher in recently 
diagnosed diabetics (duration less than 5 years) as it represents 53%. Thus the overall prevalence 
of obesity was higher than previously reported [98, 99], this difference may reflect the change in 
the life style and dietary habits. 
The prevalence of the different complications observed in the diabetic patients was nearly similar 
to that reported in from other African countries [159] and less than that found in other studies [160, 
161,162].  There is no indication that the African diabetics are less vulnerable to complications of 
the disease, a fact which has become apparent with better follow up. 
Our study showed an apparent increase in the prevalence of complications compared to El Mahdi 
study in 1991 [99]. This increase may be due to late diagnosis of diabetes, poor metabolic control 
and non standardized diagnostic procedures, delay  detection of different diabetic complications 
and this was apparent in our study as 67.7 % of the complicated patients were on regular medical 
follow up in specialized diabetic health centers or in private clinics. 
Microangiopathic complications in type 2 diabetes mellitus were significantly related to the 
duration of the disease as shown in other studies [99, 159].  The longer the duration of diabetes, the 
greater the chance that complications will occur. However in this study the macroangiopathic 
complications diagnosed were significantly related to ageing and not to the duration of diabetes. 
The patients with macroangiopathy were significantly older than the patients without 
microangiopathy, and there was no significant difference in the duration of the disease between the 
two groups.  
Hyperglycemia does not seem to play a major role in the prevalence of nephropathy, neuropathy 
and coronary heart disease in our patients as shown by other workers [163, 164].   There was no 
significant difference between the frequency of these complications in the controlled and 
uncontrolled patients.  
However a significant difference was found in patients who had cataract and diabetic retinopathy 
(P <0.01) regarding hyperglycemia and metabolic control. It is worth to note that patients usually 
become aware of the importance of metabolic control when they start to develop complications of 
diabetes. This might explain the insignificant role of hyperglycemia in relation to nephropathy, 
neuropathy and coronary heart disease. The commonest complication in this study was diabetic 
nephropathy. The incidence of micoalbuminuria and its association risk factors was examined in 
this study. The prevalence was 33%, with similar frequency to Tanzania and United States [159, 
105],  but lower than Nigeria [91], and was much higher than the  previous reported figure in  
Sudan [99].  Most of the patients were poorly controlled and their mean fasting blood glucose was 
more than 12.2 mmol/L. Hyperglycemia has a major role in the development and progression of 
diabetic nephropathy [167], it was found that irrespective of the duration and type of diabetes the 
damage to the kidney can be  avoided if good glycemic control is achieved [168]. 
The age of onset of microalbuminuria was ± 48.6, which was higher than that of diabetics with 
normoalbuminuria, however the difference was not significant P > 0.015.   It is known that the 
incidence of hypertension and diabetes increases   with age and, as a consequence, the incidence of 
persistent albuminuria (and microalbuminuria) also increases with age [169]. There was no 
significant difference in the prevalence of microalbuminuria between men and women as was 
shown also by [170, 171], while McLaughlin [169], showed that it was more common among 
males. Microalbuminuria appears earlier in our group, in contrast to other report [165].  The mean 
duration of diabetes was 7 years ±SE 0.82, and  nearly 50% of the patients  developed 
microalbuminuria before 5 years of diabetes duration.  This could be related to a long period of 
undetectable hyperglycemia before diagnosis of diabetes, hypertension, dyslipidema, as well as 
genetic and environmental factors [166]. No significant association was found between smoking 
and the occurrence of diabetic nephropathy, as shown also by another study [172]. We found that 
hypertension and obesity were not significant risk factors for the development of microalbuminuria 
in type 2 diabetic patients.   In this study microalbuminuria had strong  associations with diabetic 
retinopathy, neuropathy, and cardiovascular disease as was also reported  in other studies  
[173,174]. Microalbuminuria can be used as a marker for endothelial dysfunction, vascular injury, 
renal disease and cardiovascular disease [175]. 
Eye complications were detected in 188 patients (Cataract 18.5% and diabetic retinopathy 28 %) 
which was higher than ELMahdi's [99]. The prevalence of diabetic retinopathy (DR) was so 
characteristic, that its presence has been incorporated into the nosologic definition of type 2 
diabetes mellitus. Only hyperglycemia of sufficient magnitude to be associated with retinopathy is 
classified as type 2 DM, while lower levels of hyperglycemia that are not accompanied by 
retinopathy are classified as impaired glucose [176]. Delayed, diagnosis and detection of DR was 
apparent in about 70 % of the patients who were on regular medical follow up.  Education was 
recognized as an important risk factor for the development of DR. Diabetic retinopathy was 
detected in only 14.9 % of the patients received university and higher degree studies while it was 
found in 55.3% among the illiterates (P=0.002).  
The natural history of retinopathy in type 2 diabetes mellitus  is more difficult to delineate, since 
type 2 DM may be present for many years before it is diagnosed. As a result, in our group 16.5 % 
of patients with type 2  DM had retinopathy at the time of first diagnosis of diabetes,  and most 
developed some degree of retinopathy over time, 40% within 15 years and 43.6  % after 20 years 
duration. Age, Duration of diabetes, and hyperglycemia have been identified as important risk 
factors for the onset and progression of DR [177].  
Most of our eye complicated patients were on sulfonylurea and insulin therapy.  Hypoglycemia is 
an underappreciated and potentially fatal complication of insulin and sulfonylurea treatment. Both 
therapies were unlike Metformin, as they have no role in the prevention of vascular complications 
[178]. 
In our study, patients with retinopathy had a longer duration of diabetes and more poorly 
controlled than patients without it, as indicated by a lower body mass index, a higher frequency of 
insulin therapy, higher fasting blood glucose level, and a high albumin excretion rate as indicated 
by high albumin/ creatinine ratio. Since these metabolic factors, which have been shown to be 
individually related to retinopathy, are correlated with one another and reflect poor metabolic 
control. Albuminuria was strongly associated with presence of DR (p= 0.000). Albuminuria is not 
only an indication of renal disease, but a new independent risk marker of proliferative retinopathy 
and macroangiopathy [179].  Although hypertension is a serious risk factor for the onset and 
progression of DR in type 2 DM, in our study   no relationship between DR and high blood 
pressure was found [180]. 
    Serum lipids were found to be associated with retinopathy in this study. The reported associations 
of serum lipids with retinopathy have been consistent; however   two large studies, the Early 
Treatment Diabetic Retinopathy study and the Wisconsin Epidemiological study, showed serum 
lipids to be associated with an increased risk of hard exudates formation, [181, and 182]. 
   We found a strong correlation between DR with diabetic neuropathy P= 0.000, same as previously 
reported [183]. Diabetic retinopathy has been shown to be associated with increased cardiovascular 
mortality in diabetes mellitus (DM) patients. However, it is not well known whether the presence 
of retinopathy is a predictor of adverse cardiovascular events in diabetic patients. In our group 
there was no significant correlation between diabetic retinopathy and ischemic heart changes 
P=0.196. In our study we found the level of 1-1 allele was higher in patients with DR than the 
control group but the difference was not significant. The development of diabetic retinopathy has 
been related to hyperglycemia- induced oxidative stress, and haptoglobin is one of many 
antioxidant proteins. Its antioxidant ability is more marked among Hp 1-1 allele. Haptoglobin also 
increases serum viscosity and this could be the mechanism by which it plays a role in pathogenesis 
of diabetic retinopathy [184, 185]. We found no relationship between the haptoglobin phenotype 
and diabetes mellitus nor with diabetic retinopathy, were the same results received by [186, 187, 
&188].  
Haptoglobin as a risk factor and its role in predicting those who are susceptible to diabetic 
retinopathy and others who are protected is still a matter of controversery. Further identification of 
risk factors and determinants for retinopathy is important to improve understanding of the disease 
mechanisms, and to facilitate new treatments and preventive strategies. Diabetic retinopathy is both 
a treatable and often preventable condition. Regular screening for diabetic retinopathy and more 
aggressive management of glycemia could reduce the numbers of people who develop vision-
threatening retinopathy. 
The prevalence of diabetic peripheral neuropathy (PN), was 16.7% compared with previous studies 
ranging from <5 % to 20 -0 %. [189, 190], while in Sudan it was 28.1 % [99].  
The prevalence of PN rises with increasing age, hyperglycemia, duration, smoking, and increased 
height [190], in our group there was a significant correlation between PN, age, duration and 
smoking. No significant difference was found in the mean fasting blood glucose level and the 
height.  In only one report male sex was found to be a risk factor for PN [191].  Although female 
population was greater, in our study, sex had little impact on the frequency of PN in the present 
study (OR: 0.832). Patients on insulin therapy were more susceptible to DN, this may be due to 
tight blood glucose control as sudden lowering of nerve blood flow, following the fall in blood 
glucose level, perhaps stimulating abnormal new vessels formation which steals blood flow from 
the nerve core; this phenomenon is called "insulin neuritis" [3]. 
Hypertension and hypercholesterolemia were also reported to be important risk factors for 
development of PN [192]. In our study hypertension and hypercholesterolemia found to have little 
impact on the frequency of D N,          P > 0.05. 
A significant correlation was found between diabetic neuropathy and other complications, which 
could mean that they may have common pathogenic pathways.  
The prevalence of coronary heart disease (CHD) was 11% which was higher than that encountered 
in Sudan, before (4.4%) [99].   Diabetic patients in western countries have a markedly increased 
incidence of ischemic heart disease [159].  Until recently African have been considered to be at 
extremely at low risk for athermanous disease, but recent reports have demonstrated that African 
diabetics are susceptible to ischemic heart disease, also minor ECG abnormalities may arise from 
nutritional or infectious causes, or from diabetes mellitus per se. It may be necessary to establish 
new criteria for ECG diagnosis in Africans [159]. 
The increase prevalence of coronary heart disease in Sudan may be related to lifestyle modification 
and increase average of body mass index. In the El -Mahdi 1991 study, obesity was found in 
58.4% of the patients in our group it was found in 72 %. The overall incidence of CHD is lower in 
women, the female advantage is known to disappear in subjects with type 2 diabetes, and the risk is 
sometimes even considered to be higher in women than in men [193], although women in our result 
were more prone to the risk of CHD, the difference was not strongly significant P >0.05.  Most of 
the patients (59.6 %), were receiving, oral hypoglycemic drugs and it was concluded previously 
that treatment with either oral hypoglycemic drugs or insulin does not affect the incidence of acute 
cardiovascular disease in patients with type 2 diabetes [194].  
The lipid profile in our group was reasonable compared to that outlined in the National Cholesterol 
Education Program (NCEP) report, which are similar for younger and older patients.  [195].  
Microalbuminuria was found to be an important risk factor for cardiovascular disease in non 
insulin dependent diabetes mellitus patients (OR=2.236 with 95% CI 1.064 - 4.697). The 
pathogenic mechanism between microalbuminuria and cardiovascular disease had not been 
established, but hypercoagulability or decreased fibrinolysis have been related to cardiovascular 
disease, whereas abnormalities in homeostasis have been demonstrated in diabetic patients with an 
increased albumin excretion rate [196]. No significant association was found between ischemic 
heart changes and other microvascular complications. 
 The haptoglobin phenotypes frequency among the healthy controls showed that Hp 2-1 the highest 
(58.5 %) followed by Hp 2-2 (24.5%) and Hp 1-1 (17%) similar results have been reported earlier 
in Sudan [129, 197, & 198].  While in the diabetic patients the homozygous Hp 1-1 and 2-2 was 
higher than the controls, and Hp 2-1 was less. However the difference between the two groups was 
not significant.  This   result suggests that type 2 diabetes mellitus is Hp phenotype independent 
[142, 186, 187, & 199].  It was reported that there was, no even a relationship between Hp-
phenotype and Insulin dependent diabetes mellitus [200]. 
Hp 1-1 phenotype was maximal in the western region group, and absent completely 
among the central, eastern and southern regions, however the sample studied was not 
representative for the latter three regions. 
Hp 2-1 represented the highest value among the complicated and uncomplicated patients as it was 
52.9 % and 48.7 % respectively.  Hp phenotype 1-1 was more pronounced among complicated 
group (63.4%), than the uncomplicated (36.6%) p>0.05. Hp genotype is an independent risk factor 
for diabetic vascular complications. Some studies have presented a compelling argument that 
diabetic individuals homozygous for the Hp 1-1 allele are at decreased risk of developing vascular 
complications, compared to diabetic individuals with the Hp 2 allele [141, 201].   
It was recently demonstrated that diabetic individuals homozygous for the Hp 2 allele (Hp 2-2) 
were at 500% greater risk of cardiovascular disease (CVD) compared with diabetic individuals 
homozygous for the Hp 1 allele (Hp 1-1) [202, 203]. In another reported study [140] showed a 
significant decrease in Hp 2-1 among diabetic patients suggesting protection for heterozygote in 
patients with diabetic retinopathy. The overall prevalence of the heterozygous 2-1 haptoglobin 
phenotype among different diabetic complications was 50%, similar to that of the reference 
Sudanese population [129, 197, &198], while the level of 1-1 allele was higher among various 
complications than the control group but the difference is not significant. Haptoglobin as a risk 
factor and its role in predicting those who are susceptible to diabetic complications and others who 
are protected is still a matter of controversery [186]. 
Hp phenotype was found not to be correlated to age, sex and body mass index.  
 In our study the associations between different haptoglobin phenotypes and hypertension 
were weak and nonsignificant [122]. 
 In our study we tested the association between Hp phenotypes and some of the leading 
causes of chronic renal failure. Most of the patients (39.6%) on hemodialysis were of 
unknown etiology of renal failure, followed by diabetes mellitus.  
The association between Hp and some of the leading causes of chronic renal failure, such as auto 
immunity, hypertension and diabetic nephropathy was well established [204]. Hp 1-1 phenotype 
was significantly higher in patients with CRF (60 %) compared to controls (40%) p < 0.05 and 
OR= 1.913, (CI = 0.974-3.756).  Among the different causes of chronic renal failure Hp 2-1 
phenotype was the predominantly distributed, in contrast to another study [204] which showed that 
Hp2-2 was the over-presented phenotype, it was clarified that Hp2-2 protein exhibit weak 
antioxidant activity and Hb - binding capacity, which allows accumulation of oxidants and free 
radicals generated as result of free haem iron, at a higher rate than Hp 1-1 protein.  Accumulation 
of such product leads to kidney damage. Among diabetic patients the majority were Hp2-1, 
followed by Hp 1-1 while a very small number Hp 2-2. This result may suggest that diabetics with 
the Hp 1-1 phenotype can develop diabetic nephropathy [204], which against another study [205]. 
These results suggest that both diabetes mellitus and chronic renal failure are Hp phenotype –
independent [204].  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Conclusions and Recommendations 
 
Type 2 diabetes mellitus continues to be a serious disease   that threatened  
the health and life of many Sudanese. The present study revealed a higher  
prevalence of long term diabetic complications than has previously been reported from Sudan.  
Although most of them were on regular medical follow up, but they were poorly controlled and this emphasized 
the grave problems of diabetes care and management that are result in poor glycemic control, increased 
morbidity and a low quality of life. There is a need for an action to be taken to improve care of diabetics in 
Sudan in order to prevent complications. 
 
Recommendations: 
• Early detection and diagnosis of impaired glucose tolerance and diabetes mellitus by integration of 
diabetes control in primary health care programmes where by staff at health centers or below should be 
able to suspect diabetes.  
• Continuous education and increased awareness of the patients, about improving their dietary knowledge, 
control of body weight, increase   physical activity and early screening for diabetic complications. 
• Diabetic patients seen in different referred clinics should be examined for the delayed diabetic 
complications, especially those with longer durations of diabetes. 
• The increased prevalence of complications among Sudanese type 2 diabetic patients may reflect a 
function of the degree of genetic admixture, so more studies are needed to clarify the genetic role.  
• Early detection of microalbuminuria, as it can be used as a marker for endothelial dysfunction, vascular 
injury, renal disease and cardiovascular disease. 
• An expanded study is needed to determine the normal distribution of  haptoglobin phenotypes among 
the different ethnic groups in Sudan. 
• More studies and research are needed to clarify the role of haptoglobin as molecular marker associated 
with type 2 diabetes mellitus and the susceptibility for development of different vascular diabetic 
complications.  
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